


chain nodes :
 7 14 15 16 17 18 19 20 21 22 23 24 25 27 28
 ring nodes :
 1 2 3 4 5 6 8 9 10 11 12 13
 chain bonds :
 1-8 2-15 3-14 5-7 7-27 11-28 15-16 16-17 17-18 17-21 18-19 19-20 19-22 20-23
 23-24 23-25
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
 exact/norm bonds :
 5-7 7-27 17-21 19-22 23-24 23-25
 exact bonds :
 1-8 2-15 3-14 11-28 15-16 16-17 17-18 18-19 19-20 20-23
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
 isolated ring systems :
 containing 1 : 8 :

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom 11:Atom
 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS
 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 27:CLASS 28:CLASS

10/576,774 (formula 8)

=>

Uploading C:\Program Files\Stnexp\Queries\10576774 (formula 8).str



chain nodes :

7 14 15 16 17 18 19 20 21 22 23 24 25 27

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13

chain bonds :

1-8 2-15 3-14 5-7 7-27 15-16 16-17 17-18 17-21 18-19 19-20 19-22 20-23
23-24 23-25

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

5-7 7-27 17-21 19-22 23-24 23-25

exact bonds :

1-8 2-15 3-14 15-16 16-17 17-18 18-19 19-20 20-23

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

isolated ring systems :

containing 1 : 8 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 27:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam

10/576,774 (formula 8)

SAMPLE SEARCH INITIATED 10:48:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 13 TO ITERATE


100.0% PROCESSED 13 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 44 TO 476
PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> =>

Uploading C:\Program Files\Stnexp\Queries\10576774 (formula 8 a).str



chain nodes :

7 14 15 16 17 18 19 20 21 22 23 24 25 27 28

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13

chain bonds :

1-8 2-15 3-14 5-7 7-27 11-28 15-16 16-17 17-18 17-21 18-19 19-20 19-22
20-23 23-24 23-25

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

5-7 7-27 17-21 19-22 23-24 23-25

exact bonds :

1-8 2-15 3-14 11-28 15-16 16-17 17-18 18-19 19-20 20-23

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

isolated ring systems :

containing 1 : 8 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 27:CLASS
28:CLASS

10/576,774 (formula 8)

L3 STRUCTURE UPLOADED

=> d 13
L3 HAS NO ANSWERS
L3 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s 13 sss sam
SAMPLE SEARCH INITIATED 10:50:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 13 TO ITERATE

100.0% PROCESSED 13 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 44 TO 476
PROJECTED ANSWERS: 5 TO 234

L4 5 SEA SSS SAM L3

=> => s 13 sss ful
FULL SEARCH INITIATED 10:50:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 395 TO ITERATE

100.0% PROCESSED 395 ITERATIONS 183 ANSWERS
SEARCH TIME: 00.00.01

L5 183 SEA SSS FUL L3

=> => s 15
L6 2089 L5

=> s crystal?
L7 2268045 CRYSTAL?

=> s 16 and 17
L8 55 L6 AND L7

=> d 18 1-55 bib,ab,hitstr

L8 ANSWER 1 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2010:1626467 CAPLUS
 TI Novel acetylsalicylic acid salts
 IN Kalvins, Ivars; Birmans, Anatolijs; Veveris, Maris; Labedevs, Antons;
 Misnovs, Anatolijs
 PA Tetra, Sia, Latvia
 SO PCT Int. Appl., 41pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2010151095	A1	20101229	WO 2010-LV7	20100621
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI LV 2009-117 A 20090625

LV 2010-95 A 20100621

AB Novel betaine salts of acetylsalicylic acid, namely
 4-trimethylammoniobutanoate acetylsalicylate, Z-carnitine acetylsalicylate
 and 3-(trimethylammonioamino)-propanoate (meldonium) acetylsalicylate.
 Use of meldonium acetylsalicylate as antiplatelet agent for treating
 various pathologies induced by platelet aggregation, anti-inflammatory and
 antihyperlipidemic agent.

IT 1259394-79-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (novel acetylsalicylic acid salts and pharmacol. thereof and use with
 other agents)


RN 1259394-79-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 287714-41-4
 CMF C22 H28 F N3 O6 S

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




CM 2

CRN 76144-81-5
CMF C6 H14 N2 O2

Me₃N⁺ NH—CH₂—CH₂—CO₂⁻

CM 3

CRN 50-78-2
CMF C9 H8 O4



RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2010:1601777 CAPLUS
 DN 154:73129
 TI Crystalline form of pemirolast sodium hemihydrate
 IN Perlberg, Anett; Viertelhaus, Martin; Rosenstroem, Ulrika; Horvath, Karol
 PA Cardoz AB, Swed.
 SO PCT Int. Appl., 68pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2010146348	A2	20101223	WO 2010-GB1168	20100615
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2009-187348P P 20090616
 US 2009-187355P P 20090616


AB There is provided a hemihydrate form of the sodium salt of pemirolast sodium hemihydrate is prepared from pemirolast free acid which is treated with NaOMe in MeOH. The crystal form is characterized and properties determined

IT 287714-41-4, Rosuvastatin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (crystalline form of pemirolast sodium hemihydrate)

RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



L8 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2010:1601776 CAPLUS
 DN 154:73128
 TI New crystalline form of pemirolast
 IN Perlberg, Anett; Viertelhaus, Martin
 PA Cardoz AB, Swed.
 SO PCT Int. Appl., 57pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2010146341	A2	20101223	WO 2010-GB1159	20100615
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2009-187348P P 20090616

AB There is provided a hydrate form of the sodium salt of pemirolast. Thus, tablet comprised (in wt%): pemirolast heptahydrate 4.7, Isomalt DC 100 57.5, microcryst. cellulose 37.0, magnesium stearate 0.73.


IT 287714-41-4, Rosuvastatin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (crystalline hydrate form of pemirolast sodium salt)

RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



L8 ANSWER 4 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2010:1464239 CAPLUS
 DN 153:651632
 TI Dry powder inhalers
 IN Hodson, Peter D.; Stein, Stephen W.; Chiou, Herbert C.; Wang, Zhaolin;
 Robison, Thomas S.; Domroese, Michael K.; Walburg, Blake D.
 PA 3M Innovative Properties Company, USA
 SO PCT Int. Appl., 51pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2010135340	A2	20101125	WO 2010-US35280	20100518
		W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2009-179220P P 20090518

AB Dry powder inhalers and dry powder inhaler storage cassettes including a compartment housing an elongate carrier preloaded with a plurality of doses of finely divided powder comprising a biol. active substance, the compartment being configured such that said preloaded doses are sealed within said compartment and such that the carrier may be advanced from the compartment to the chamber through an exit provided with a moisture barrier sealing system, wherein the moisture barrier sealing system is configured and arranged such that it is relaxable during advancement of the carrier, said sealing system being in sealing configuration prior to an advancement of the carrier, relaxed upon an advancement of the carrier and returned to its sealing configuration at the latest after release of the powder associated with said area of the carrier.

IT 287714-41-4, Rosuvastatin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (dry powder inhalers)

RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



L8 ANSWER 5 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2010:1249811 CAPLUS

DN 153:515045

TI Progressive emulsion crystallization for drug purification

IN Kljajic, Alen; Zupez, Rok

PA Krka, d.d., Novo Mesto, Slovenia

SO PCT Int. Appl., 79pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2010112222	A1	20101007	WO 2010-EP2078	20100331

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG,
 ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP,
 KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA,
 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE,
 PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV,
 SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
 SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ,
 UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI SI 2009-87 A 20090331

AB The invention described is in the field of separation processes, more particularly, in the field of selective crystallization methods for purification of organic substances. E.g., ezetimibe is purified by progressive emulsion crystallization

IT 287714-41-4P, Rosuvastatin


RL: PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (progressive emulsion crystallization for drug purification)

RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.




RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2009:1501900 CAPLUS
 DN 152:12374
 TI Preparation method of rosuvastatin calcium and its intermediates
 IN Chen, Benshun; Wang, Bing; Jin, Xiaofeng; Zou, Lin
 PA Changzhou Pharmaceutical Factory, Peop. Rep. China
 SO PCT Int. Appl., 44pp.
 CODEN: PIXXD2
 DT Patent
 LA Chinese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009143776	A1	20091203	WO 2009-CN72018	20090527
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	CN 101591301	A	20091202	CN 2008-10110709	20080527
	CN 101591302	A	20091202	CN 2008-10110711	20080527
PRAI	CN 2008-10110709	A	20080527		
	CN 2008-10110711	A	20080527		
OS	CASREACT 152:12374; MARPAT 152:12374				
AB	The preparation method of rosuvastatin calcium, which can be used for the production of medicament lowering the levels of LDL-cholesterol and triglycerides in vivo, is provided. Rosuvastatin calcium was prepared via Wittig reaction of Me (R)-3-{{(1,1-dimethylethyl)dimethylsilyl}oxy}-5-oxo-6-(triphenylphosphono)hexanoate with N-{4-(4-fluorophenyl)-5-formyl-6-(1-methylethyl)-2-pyrimidinyl}-N-methylmethanesulfonamide; the resulting Me (3R,6E)-3-{{(1,1-dimethylethyl)dimethylsilyl}oxy}-7-{4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl}-5-oxo-6-heptenoate underwent desilylation to give the corresponding alc., which underwent reduction to give the 1,3-diol derivative, which underwent hydrolysis to give the acid, which underwent esterification with isopentyl bromide to give the ester, which underwent hydrolysis and salt formation to give the title compound Such preparation method is suitable for industrial production Furthermore, the intermediate crystallines used in the preparation method are provided.				
IT	147118-40-9P	1197348-98-3P			
	RL: IMF (Industrial manufacture); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation method of rosuvastatin calcium and its intermediates by using Wittig reaction as the key step)				
RN	147118-40-9	CAPLUS			
CN	6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, methyl ester, (3R,5S,6E)- (CA INDEX NAME)				

Absolute stereochemistry.
Double bond geometry as shown.




RN 1197348-98-3 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, 3-methylbutyl ester, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 147098-18-8P 287714-41-4P
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation method of rosuvastatin calcium and its intermediates by using Wittig reaction as the key step)
 RN 147098-18-8 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, sodium salt (1:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




● Na

RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



IT 147098-20-2P, Rosuvastatin calcium

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation method of rosuvastatin calcium and its intermediates by using Wittig reaction as the key step)


RN 147098-20-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt

10/576,774 (formula 8)

(2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



● 1/2 Ca

RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 7 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2009:1435256 CAPLUS
 DN 151:528789
 TI Pyrimidine derivatives and medical application
 IN Taylor, Nigel Philip; Okada, Tetsuo
 PA AstraZeneca UK Ltd., UK; Shionogi & Co., Ltd.
 SO Taiwan., 12pp.
 CODEN: TWXXA5
 DT Patent
 LA Chinese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	TW 292396	B	20080111	TW 2001-106339	20010319
PRAI	TW 2001-106339		20010319		
AB	The disclosed pyrimidine derivs. are (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyheptyl-6-ene-oic acid crystal salt I (M = ammonium, methylammonium, ethylammonium, dihydroxyethylammonium, hydroxymethylammonium, benzylammonium, 4-methoxybenzylammonium, lithium, magnesium) with X-ray powder diffraction spectra 2-theta = 12.9, 15.2, 18.0, 18.2, 18.5, 20.2, 22.4, 23.0, 24.0 and 27.2 special peak. The claimed compds. were prepared by direct salification of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyheptyl-6-ene-oic acid with amine or base in acetonitrile or Et acetate. The obtained compds. or their pharmaceutical composite can be used for treating HMG-CoA reductase related diseases without data.				
IT	1194303-33-7P	1194303-35-9P	1194303-36-0P		
	1194303-37-1P	1194303-38-2P	1194303-39-3P		
	1194303-40-6P	1194303-41-7P			
	RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of pyrimidine derivs. and medical application)				
RN	1194303-33-7 CAPLUS				
CN	6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methylsulfonyl]amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-, compd. with methanamine (1:1) (CA INDEX NAME)				

CM 1

CRN 371775-74-5
 CMF C21 H26 F N3 O6 S

Absolute stereochemistry.
 Double bond geometry as shown.




CM 2

CRN 74-89-5
CMF C H5 N $\text{H}_3\text{C}-\text{NH}_2$ RN 1194303-35-9 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-, compd. with ethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 371775-74-5
CMF C21 H26 F N3 O6 SAbsolute stereochemistry.
Double bond geometry as shown.



CM 2


CRN 75-04-7
CMF C2 H7 N $\text{H}_3\text{C}-\text{CH}_2-\text{NH}_2$

RN 1194303-36-0 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-, compd. with 2'-iminobis[ethanol] (1:1) (CA INDEX NAME)

CM 1

CRN 371775-74-5
CMF C21 H26 F N3 O6 S

Absolute stereochemistry.
 Double bond geometry as shown.




CM 2

CRN 111-42-2
CMF C4 H11 N O2HO—CH₂—CH₂—NH—CH₂—CH₂—OHRN 1194303-37-1 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-, compd. with 1-(methylamino)methanol (1:1) (CA INDEX NAME)

CM 1

CRN 371775-74-5
CMF C21 H26 F N3 O6 SAbsolute stereochemistry.
Double bond geometry as shown.




CM 2

CRN 3400-38-2
CMF C2 H7 N OHO—CH₂—NH—CH₃RN 1194303-38-2 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-, compd. with benzenemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 371775-74-5
CMF C21 H26 F N3 O6 SAbsolute stereochemistry.
Double bond geometry as shown.




CM 2

CRN 100-46-9
CMF C7 H9 N $\text{H}_2\text{N}-\text{CH}_2-\text{Ph}$ RN 1194303-39-3 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-, compd. with 4-methoxybenzenemethanamine (1:1) (CA INDEX NAME)

CM 1


CRN 371775-74-5
CMF C21 H26 F N3 O6 SAbsolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 2393-23-9


CMF C8 H11 N O



RN 1194303-40-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, lithium salt (1:1),
(3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




● Li

RN 1194303-41-7 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, magnesium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



● 1/2 Mg

IT 1194303-42-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyrimidine derivs. and medical application)

RN 1194303-42-8 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1),
(3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



● 1/2 Ca

L8 ANSWER 8 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2009:1368423 CAPLUS
 DN 152:51216
 TI Drug Effects Viewed from a Signal Transduction Network Perspective
 AU Fliri, Anton F.; Loging, William T.; Volkmann, Robert A.
 CS Pfizer Global Research and Development, Groton, CT, 06340, USA
 SO Journal of Medicinal Chemistry (2009), 52(24), 8038-8046
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 AB Understanding how drugs affect cellular network structures and how resulting signals are translated into drug effects holds the key to the discovery of medicines. Herein we examine this cause-effect relationship by determining protein network structures associated with the generation of specific in vivo drug-effect patterns. Medicines having similar in vivo pharmacol. have been identified by a comparison of drug-effect profiles of 1320 medicines. Protein network positions reached by these medicines were ascertained by examining the coinvestigation frequency of these medicines and 1179 protein network constituents in millions of scientific investigations. Interestingly, medicine assocns. obtained by comparing by drug-effect profiles mirror those obtained by comparing drug-protein coinvestigation frequency profiles, demonstrating that these drug-protein reachability profiles are relevant to in vivo pharmacol. By using protein assocns. obtained in these investigations and independent, curated protein interaction information, drug-mediated protein network topol. models can be constructed. These protein network topol. models reveal that drugs having similar pharmacol. profiles reach similar discrete positions in cellular protein network systems and provide a network view of medicine cause-effect relationships.
 IT 147098-20-2, Rosuvastatin Calcium
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (drug effects viewed from a signal transduction network perspective)
 RN 147098-20-2 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



● 1/2 Ca

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2009:1294870 CAPLUS
 DN 151:470226
 TI Preparation of crystalline methyl
 7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-
 methylsulfonylamino)pyrimidin-5-yl]-(3R)-3-hydroxy-5-oxo-6(E)-heptenoate
 as a rosuvastatin intermediate.
 IN Mahajan, Sanjay; Sethi, Madhuresh; Ray, Purna Chandra; Datta, Debashish
 PA Matrix Laboratories Limited, India
 SO PCT Int. Appl., 15 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009128091	A2	20091022	WO 2009-IN116	20090220
	WO 2009128091	A3	20101104		
		W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA	

PRAI IN 2008-CH430 A 20080220

OS CASREACT 151:470226

AB A crystalline form of Me 7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(3R)-3-hydroxy-5-oxo-6(E)-heptenoate (I) having a specified X-ray diffraction pattern was prepared. Thus, Me 7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6(E)-heptenoate (preparation given) was refluxed 7-8 h with CuCl₂.2H₂O in acetone/H₂O. The residue was heated in Me₂CHOH to 40-45° followed by cooling to 10-15° to obtain crystalline I.

IT 147098-18-8P, Rosuvastatin sodium 147098-20-2P,
 Rosuvastatin calcium


RL: IMF (Industrial manufacture); PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of crystalline

fluorophenylisopropylmethylmethysulfonylaminopyrimid
 inyldihydroxyheptenoate as a rosuvastatin intermediate)

RN 147098-18-8 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, sodium salt (1:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




● Na

RN 147098-20-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




● 1/2 Ca

IT 287714-41-4P, Rosuvastatin

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (preparation of crystalline
 fluorophenylisopropylmethylethylsulfonylaminopyrimid


inylidihydroxyheptenoate as a rosuvastatin intermediate)
 RN 287714-41-4 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



IT 147118-40-9P
 RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of crystalline
 fluorophenylisopropylmethylnethylsulfonylaminopyrimid
 inylidihydroxyheptenoate as a rosuvastatin intermediate)
 RN 147118-40-9 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, methyl ester,
 (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



L8 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2009:1149121 CAPLUS
 DN 152:238793
 TI Preparation of novel amine salts of statin drugs
 IN Reddy, Manne Satyanarayana; Eswaraiah, Sajja; Reddy, Maramreddy Sahadeva;
 Prasad, Durgadas Shyla
 PA MSN Laboratories Limited, India
 SO Indian Pat. Appl., 31pp.
 CODEN: INXXBQ
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI IN 2008CH00353	A	20090911 20080211	IN 2008-CH353	20080211


PRAI IN 2008-CH353
 OS CASREACT 152:238793; MARPAI 152:238793

AB The present invention relates to a new salt of a drug with an amine salt, characterized in that said amine is selected from the group consisting of amine I [each R₁ and R₂ are independently selected from a hydrogen atom, a straight or a branched alkyl group having 1 to 4 carbon atoms and n denotes an integer from 0 to 5]. Thus, montelukast amine salt II·III was prepared from quinoline IV via mesylation with MeSO₂Cl in PhMe/MeCN containing EtN(CH₂Me)₂; sulfuration with Me 1-(mercaptomethyl)cyclopropaneacetate in DMSO containing NaOMe; saponification with aqueous NaOH; and salt formation with 2-(2-aminoethyl)thiophene in PhMe.

IT 287714-41-4, Rosuvastatin
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (amine salt formation of; preparation of novel amine salts of statin drugs)

RN 287714-41-4 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




IT 147098-20-2P, Rosuvastatin calcium

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of novel amine salts of statin drugs)

RN 147098-20-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



● 1/2 Ca

IT 1207428-75-8P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
 USES (Uses)
 (preparation, x-ray and DSC anal., and calcium salt formation of;
 preparation of
 novel amine salts of statin drugs)

RN 1207428-75-8 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 287714-41-4


CMF C22 H28 F N3 O6 S

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



CM 2

CRN 30433-91-1
CMF C₆ H₉ N S



L8 ANSWER 11 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2009:944375 CAPLUS
 DN 151:229395
 TI Modified release formulations of HMG CoA reductase inhibitors
 IN Kulkarni, Sheetal; Das, Srirupa; Deshmukh, Ashish Ashokrao; Dalal, Satish
 Kumar; Kulkarni, Shirishkumar
 PA Lupin Limited, India
 SO PCT Int. Appl., 37pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009095934	A1	20090806	WO 2009-IN69	20090130
	W: AE, AG, AL, AM, AO, AT, AU	AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2009208610	A1	20090806	AU 2009-208610	20090130
	MX 2010008466	A	20101025	MX 2010-8466	20100730
	US 20110003837	A1	20110106	US 2010-865448	20100730
PRAI	IN 2008-KO145	A	20080130		
	WO 2009-IN69	W	20090130		


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Modified release formulations of HMG CoA reductase inhibitors are claimed, which provide reduced incidence of rhabdomyolysis, renal toxicity and other side effects by increasing hepatic bioavailability and decreasing systemic availability upon oral administration. The modified release pharmaceutical formulation comprises a therapeutically effective amount of HMG CoA reductase inhibitor or a pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), prodrug or metabolite thereof, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein the modified release formulation provides reduced incidence of adverse effects and improved efficacy when compared to the immediate release formulation upon oral administration. Coated tablets were prepared from rosuvastatin calcium 2, HPMC 11, croscarmellose sodium 15, microcryst. cellulose 27, Aerosil 0.5, lactose 43, and magnesium stearate 1.5 % weight/weight, with film coating q.s. An in vitro dissoln. study and an in vivo bioequivalence study were done on the tablet formulation.

IT 147098-20-2, Rosuvastatin calcium 287714-41-4,
 Rosuvastatin 287714-41-4D, Rosuvastatin, salts, polymorphs,
 solvates, hydrates, prodrugs, or metabolites
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (modified release formulations of HMG CoA reductase inhibitors with
 reduced side effects and increased hepatic bioavailability)
 RN 147098-20-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




● 1/2 Ca

RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-

10/576,774 (formula 8)

[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2009:620878 CAPLUS
 DN 150:572385
 TI New crystalline di-Ph acetidinone hydrate with improved solubility, method for preparation and use as hypolipemic agent
 IN Wollmann, Theodor Andreas; Duffy, Regina; Cullmann, Frank
 PA Sanofi-Aventis Deutschland G.m.b.H., Germany
 SO PCT Int. Appl., 81 pp.
 CODEN: PIXXD2

DT Patent
 LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009062619	A1	20090522	WO 2008-EP9323	20081106
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	DE 102007054497	B3	20090723	DE 2007-102007054497	20071113
	EP 2220040	A1	20100825	EP 2008-850642	20081106
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
PRAI	DE 2007-102007054497	A	20071113		
	US 2007-990255P	P	20071126		
	DE 2007-102007063671	A	20071113		
	WO 2008-EP9323	W	20081106		

AB The invention relates to a crystalline hydrate of formula (I) wherein n has a value of 0.5 to 1.8. The title compound is prepared from its amorphous anhydrous

form by crystallization in aqueous ethanol. The hydrate compound's dissoln. rate is

higher than that of the amorphous form. The crystalline di-Ph acetidinone hydrate is used as hypolipidemic agent, also in combination with other active substances.


IT 287714-41-4, Rosuvastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (in combination with; crystalline di-Ph acetidinone hydrate with improved solubility, method for preparation and use as hypolipemic agent)

RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2009:616015 CAPLUS
 DN 150:547788
 TI Process for the modification of solid state compounds such as pharmaceuticals and co-amorphous compositions produced with same
 IN Ovokaitys, Todd F.; Strachan, John Scott
 PA USA
 SO U.S. Pat. Appl. Publ., 69 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20090131376	A1	20090521	US 2008-252458	20081016
	CA 2702903	A1	20090423	CA 2008-2702903	20081016
	WO 2009052246	A1	20090423	WO 2008-US80095	20081016
		W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW		
		RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	EP 2211611	A1	20100804	EP 2008-839613	20081016
		R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS		
PRAI	JP 2011500709	T	20110106	JP 2010-530098	20081016
	US 2007-999445P	P	20071017		
	US 2007-999462P	P	20071017		
	US 2007-999483P	P	20071017		
	US 2008-252458	A	20081016		
	WO 2008-US80095	W	20081016		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention provides a process for preparing non-crystalline organic compns. and

non-crystalline, co-amorphous blends of organic compds. In particular, the invention is directed a process for the preparation of noncryst. and crystalline

forms of chemical compds., such as pharmaceutical and nutrient compds., and to noncryst. and crystalline compds. prepared with the method of the invention. Thus, noncryst. aspirin is far from thermodn. equilibrium at room temperature, and

has always been found previously to be crystalline or to crystallize at temps. above the glass transitions temperature, which is well below room temperature, up to the melt temperature; however, the repetitive application of laser

radiation in accordance with the invention, converts aspirin to a predominant noncryst. form that has been found to remain stable at room temperature for at least up to about a year.

IT 147098-20-2, Rosuvastatin calcium


RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(modification of solid state compound such as pharmaceuticals and co-amorphous compns. produced with same by using laser radiation)

RN 147098-20-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



● 1/2 Ca

L8 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2009:486992 CAPLUS

DN 150:456443

TI Process for the modification of solid state compounds such as pharmaceuticals and co-amorphous compositions produced with same

IN Strachan, John Scott

PA Ovokaitys, Todd, F., USA

SO PCT Int. Appl., 113pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009052246	A1	20090423	WO 2008-US80095	20081016
	W: AE, AG, AL, AM, AO, AT, AU, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	CA 2702903	A1	20090423	CA 2008-2702903	20081016
	US 20090131376	A1	20090521	US 2008-252458	20081016
	EP 2211611	A1	20100804	EP 2008-839613	20081016
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
	JP 2011500709	T	20110106	JP 2010-530098	20081016
PRAI	US 2007-999445P	P	20071017		
	US 2007-999462P	P	20071017		
	US 2007-999483P	P	20071017		
	US 2008-252458	A	20081016		
	WO 2008-US80095	W	20081016		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention provides a process for preparing non-crystalline organic compns. and

non-crystalline, co-amorphous blends of organic compds. In particular, the invention is directed a process for the preparation of noncryst. and crystalline

forms of chemical compds., such as pharmaceutical and nutrient compds., and to noncryst. and crystalline compds. prepared with the method of the invention. Thus, noncryst. aspirin is far from thermodn. equilibrium at room temperature, and

has always been found previously to be crystalline or to crystallize at temps. above the glass transitions temperature, which is well below room temperature, up to the melt temperature; however, the repetitive application of laser

radiation in accordance with the invention, converts aspirin to a predominant noncryst. form that has been found to remain stable at room temperature for at least up to about a year.

IT 147098-20-2, Rosuvastatin calcium


RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(modification of solid state compound such as pharmaceuticals and co-amorphous compns. produced with same by using laser radiation)

RN 147098-20-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



● 1/2 Ca

RE.CNT 4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2009:179822 CAPLUS
 DN 150:222465
 TI Process for the preparation of methyl ester of rosuvastatin
 IN Bastarda, Andrej; Grahek, Rok; Crnugelj, Martin
 PA Lek Pharmaceuticals D.D., Slovenia
 SO PCT Int. Appl., 19pp.; Chemical Indexing Equivalent to 150:222448 (EP)
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009019211	A1	20090212	WO 2008-EP60125	20080801
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 2022784	A1	20090211	EP 2007-114009	20070808
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	EP 2185528	A1	20100519	EP 2008-786745	20080801
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				

PRAI EP 2007-114009 A 20070808
 WO 2008-EP60125 W 20080801

AB Process for the preparation of enantiomerically pure Me ester of rosuvastatin is developed, wherein the crude Me ester of rosuvastatin is first purified by preparative HPLC, followed by crystallization


IT 1112048-62-0

RL: OCU (Occurrence, unclassified); PEP (Physical, engineering or chemical process); REM (Removal or disposal); OCCU (Occurrence); PROC (Process) (preparation of chromatog. pure enantiomer of Me ester of rosuvastatin using preparative HPLC and crystallization)

RN 1112048-62-0 CAPLUS


CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, methyl ester, (3S,5R,6E)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



IT 287714-41-4P, Rosuvastatin
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of chromatog. pure enantiomer of Me ester of rosuvastatin using
 preparative HPLC and crystallization for preparation of enantiomerically
 pure
 rosuvastatin)
 RN 287714-41-4 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-
 [methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




IT 615263-54-2
 RL: OCU (Occurrence, unclassified); PEP (Physical, engineering or chemical
 process); REM (Removal or disposal); OCCU (Occurrence); PROC (Process)
 (racemic mixture; preparation of chromatog. pure enantiomer of Me ester of
 rosuvastatin using preparative HPLC and crystallization)

RN 615263-54-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, methyl ester, (3R,5S,6E)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT 147118-40-9P

RL: ANT (Analyte); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(rosuvastatin Me ester; preparation of chromatog. pure enantiomer of Me ester of rosuvastatin using preparative HPLC and crystallization)

RN 147118-40-9 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, methyl ester, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RE.CNT 5


THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/576,774 (formula 8)

L8 ANSWER 16 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2009:172869 CAPLUS
 DN 150:222448
 TI Process for the preparation of methyl ester of rosuvastatin
 PA Lek Pharmaceuticals D.D., Slovenia
 SO Eur. Pat. Appl., 14pp.; Chemical Indexing Equivalent to 150:222465 (WO)
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 2022784	A1	20090211	EP 2007-114009	20070808
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	WO 2009019211	A1	20090212	WO 2008-EP60125	20080801
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 2185528	A1	20100519	EP 2008-786745	20080801
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
PRAI	EP 2007-114009	A	20070808		
	WO 2008-EP60125	W	20080801		
AB	Process for the preparation of enantiomerically pure Me ester of rosuvastatin is developed, wherein the crude Me ester of rosuvastatin is first purified by preparative HPLC, followed by crystallization				
IT	1112048-62-0				
	RL: OCU (Occurrence, unclassified); PEP (Physical, engineering or chemical process); REM (Removal or disposal); OCCU (Occurrence); PROC (Process) (preparation of chromatog. pure enantiomer of Me ester of rosuvastatin using preparative HPLC and crystallization)				
RN	1112048-62-0 CAPLUS				
CN	6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, methyl ester, (3S,5R,6E)- (CA INDEX NAME)				

Absolute stereochemistry.
 Double bond geometry as shown.



IT 287714-41-4P, Rosuvastatin
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of chromatog. pure enantiomer of Me ester of rosuvastatin using
 preparative HPLC and crystallization for preparation of enantiomerically
 pure
 rosuvastatin)
 RN 287714-41-4 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-
 [methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




IT 615263-54-2
 RL: OCU (Occurrence, unclassified); PEP (Physical, engineering or chemical
 process); REM (Removal or disposal); OCCU (Occurrence); PROC (Process)
 (racemic mixture; preparation of chromatog. pure enantiomer of Me ester of
 rosuvastatin using preparative HPLC and crystallization)

RN 615263-54-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, methyl ester, (3R,5S,6E)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT 147118-40-9P

RL: ANT (Analyte); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(rosuvastatin Me ester; preparation of chromatog. pure enantiomer of Me ester of rosuvastatin using preparative HPLC and crystallization)

RN 147118-40-9 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, methyl ester, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/576,774 (formula 8)

L8 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2008:1300536 CAPLUS
 DN 149:519052
 TI Preparation of crystal forms of saxagliptin
 IN Gougoutas, Jack Z.; Malley, Mary F.; DiMarco, John D.; Yin, Xiaotian S.;
 Wei, Chenkou; Yu, Jurong; Vu, Truc Chi; Jones, Gregory Scott; Savage,
 Scott A.
 PA Bristol-Myers Squibb Company, USA
 SO PCT Int. Appl., 134pp.
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008131149	A2	20081030	WO 2008-US60711	20080418
	WO 2008131149	A3	20090625		
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, SU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	US 20090054303	A1	20090226	US 2008-105316	20080418
	AR 66130	A1	20090722	AR 2008-101632	20080418
	EP 2137149	A2	20091230	EP 2008-746183	20080418
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, MK, RS				
	JP 2010524966	T	20100722	JP 2010-504258	20080418
	IN 2009DN06560	A	20100611	IN 2009-DN6560	20091014
	CN 101687793	A	20100331	CN 2008-80021025	20091221
PRAI	US 2007-912950P	P	20070420		
	WO 2008-US60711	W	20080418		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Phys. crystal structures of saxagliptin are provided including the free base monohydrate thereof (form H-1) and the hydrochloride thereof, including hydrochloride containing 0.75 equiv of H₂O (form H0.75-3) and hydrochloride containing 2 equivs of H₂O (form H2-1), and hydrochloride Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compns. containing these compds. processes for preparing the same, and methods of treating diseases such as diabetes.

IT 287714-41-4


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of crystal forms of saxagliptin)

RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


Double bond geometry as shown.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L8 ANSWER 18 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2008:696589 CAPLUS
 DN 149:143220
 TI Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase
 AU Sarver, Ronald W.; Bills, Elizabeth; Bolton, Gary; Bratton, Larry D.; Caspers, Nicole L.; Dunbar, James B.; Harris, Melissa S.; Hutchings, Richard H.; Kennedy, Robert M.; Larsen, Scott D.; Pavlovsky, Alexander; Pfefferkorn, Jeffrey A.; Bainbridge, Graeme
 CS Pfizer Global Research & Development, Ann Arbor, MI, 48105, USA
 SO Journal of Medicinal Chemistry (2008), 51(13), 3804-3813
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 AB Clin. studies have demonstrated that statins, 3-hydroxy-3-methylglutaryl CoA reductase (HMGR) inhibitors, are effective at lowering mortality levels associated with cardiovascular disease; however, 2-7% of patients may experience statin-induced myalgia that limits compliance with a treatment regimen. High resolution crystal structures, thermodyn. binding parameters, and biochem. data were used to design statin inhibitors with improved HMGR affinity and therapeutic index relative to statin-induced myalgia. These studies facilitated the identification of imidazole 1 as a potent ($IC_{50} = 7.9$ nM) inhibitor with excellent hepatoselectivity (>1000-fold) and good in vivo efficacy. The binding of 1 to HMGR was enthalpically driven with a ΔH of -17.7 kcal/M. Addnl., a second novel series of bicyclic pyrrole-based inhibitors was identified that induced order in a protein flap of HMGR. Similar ordering was detected in a substrate complex, but has not been reported in previous statin inhibitor complexes with HMGR.
 IT 287714-41-4, Rosuvastatin
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (thermodn. and structure guided design of statin-based inhibitors of HMG-CoA reductase)
 RN 287714-41-4 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 19 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2008:486191 CAPLUS
 DN 149:32109
 TI A new approach to the total synthesis of rosuvastatin
 AU Andrushko, Natalia; Andrushko, Vasyl; Koenig, Gerd; Spannenberg, Anke;
 Boerner, Armin
 CS Leibniz-Institut fuer Katalyse, Universitaet Rostock e.V., Rostock, 18059,
 Germany
 SO European Journal of Organic Chemistry (2008), (5), 847-853
 CODEN: EJOCFK; ISSN: 1434-193X
 PB Wiley-VCH Verlag GmbH & Co. KGaA
 DT Journal
 LA English
 OS CASREACT 149:32109
 AB A new multi-step synthesis of the lipid-lowering agent rosuvastatin Et ester (I), involving two homogeneously catalyzed reaction steps, is described. The key building block, N-[4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl]-N-methylmethanesulfonamide (II), was prepared by Pd-catalyzed formylation with CO/H₂ (1:1, 50 bar, phosphane ligand/substrate ratio of 1:10). Several alternative pathways for the preparation of II were also tested, but were found to be inferior. Rosuvastatin precursor was assembled by Wittig coupling of aldehyde II and ylide III, derived from a Ru-catalyzed asym. hydrogenation. The second stereogenic center was finally created by stereoselective reduction with Et₂BOMe and NaBH₄ to afford rosuvastatin Et ester.
 IT 851443-04-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (asym. total synthesis of rosuvastatin Et ester)
 RN 851443-04-4 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, ethyl ester, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/576,774 (formula 8)

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 20 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2008:410715 CAPLUS
 DN 148:410747
 TI Crystalline diamine salts of rosuvastatin
 IN Dandala, Ramesh; Mallela, Sambhu Prasad Sarma; Nandi, Sukumar; Nangi,
 Gangadhar Bhima Shankar; Meenakshisunderam, Sivakumaran
 PA Aurobindo Pharma Limited, India
 SO PCT Int. Appl., 23pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008038132	A1	20080403	WO 2007-IB2880	20070924
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	IN 2006CH01807	A	20081128	IN 2006-CH1807	20060928
PRAI	IN 2006-CH1807	A	20060928		

OS MARPAT 148:410747

AB The present invention relates to crystalline rosuvastatin amine salts. Thus, the Me ester of rosuvastatin was dissolved in MeCN and treated with aqueous NaOH solution and the solution was treated with N,N'-dibenzylethylenediamine diacetate to give the desired rosuvastatin amine salt.

IT 1016160-64-7P

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (crystalline diamine salts of rosuvastatin)


RN 1016160-64-7 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-, compd. with N1,N2-bis(phenylmethyl)-1,2-ethanediamine (1:?) (CA INDEX NAME)

CM 1

CRN 287714-41-4
 CMF C22 H28 F N3 O6 S

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



CM 2


CRN 140-28-3
CMF C16 H20 N2Ph—CH₂—NH—CH₂—CH₂—NH—CH₂—Ph

IT 147098-20-2P
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (crystalline diamine salts of rosuvastatin)

RN 147098-20-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)— (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



● 1/2 Ca


IT 147118-40-9 355806-00-7 851443-04-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (crystalline diamine salts of rosuvastatin)

RN 147118-40-9 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, methyl ester, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 355806-00-7 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, 1,1-dimethylethyl ester, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.




RN 851443-04-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, ethyl ester, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 147098-18-8P 287714-41-4P, Rosuvastatin


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(crystalline diamine salts of rosuvastatin)

RN 147098-18-8 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, sodium salt (1:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.




● Na

RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 21 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2008:380441 CAPLUS
 DN 148:363530
 TI Crystalline rosuvastatin calcium
 IN Wizel, Shlomit; Niddam-Hildesheim, Valerie; Shabat, Shalom
 PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
 SO PCT Int. Appl., 21pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008036286	A1	20080327	WO 2007-US20247	20070918
	W: AE, AG, AL, AM, AT, AU, AZ	BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20080176878	A1	20080724	US 2007-901813	20070918
	EP 1948618	A1	20080730	EP 2007-838458	20070918
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	JP 2008539278	T	20081113	JP 2008-535810	20070918
	KR 2008060284	A	20080701	KR 2008-7011735	20080516
	MX 2008006438	A	20080806	MX 2008-6438	20080516
PRAI	US 2006-845584P	P	20060918		
	WO 2007-US20247	W	20070918		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Provided is a crystalline form of rosuvastatin calcium characterized by x-ray powder diffraction peaks at about 4.7, 19.4 and 22.3° 2 theta and processes for the preparation thereof. A mixture of water and the drug was stirred at 25° for 24 h. The resulting slurry was cooled, stirred, and filtered to give a powdery compound


IT 147098-20-2, Rosuvastatin calcium
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(crystalline rosuvastatin calcium)

RN 147098-20-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




● 1/2 Ca

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2007:1354107 CAPLUS
 DN 149:167107
 TI Computer-aided molecular design of novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia
 AU Da Silva, Vinicius B.; Andrioli, Willian Jonis; Carvalho, Ivone; Taft, Carlton A.; Silva, Carlos H. T. P.
 CS Departamento de Ciencias Farmaceuticas, Faculdade de Ciencias Farmaceuticas de Ribeirao Preto, Universidade de Sao Paulo, Monte Alegre, Ribeirao Preto-SP, 14040-903, Brazil
 SO Journal of Theoretical & Computational Chemistry (2007), 6(4), 811-821
 CODEN: JTCCAC; ISSN: 0219-6336
 PB World Scientific Publishing Co. Pte. Ltd.
 DT Journal
 LA English
 AB Elevated cholesterol levels are a primary risk factor for the development of coronary artery disease. Dietary changes associated with drug therapy can reduce high serum cholesterol levels and dramatically decrease the risk of stroke and overall mortality. HMG-CoA reductase is an important mol. target of hypolipemic drugs, known as statins, which are effective in the reduction of cholesterol serum levels, attenuating cholesterol synthesis in-liver by competitive inhibition regarding the substrate HMG-CoA. In this paper, we have focused on computer-aided mol. design using d. functional theory, flexible docking, mol. dynamics as well as ADME, and synthetic accessibility analyses to propose novel potential HMG-CoA reductase inhibitors, designed by bioisosteric modifications which are promising for the treatment of hypercholesterolemia.
 IT 287714-41-4, Rosuvastatin
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (computer-aided mol. design of novel HMG-CoA reductase inhibitors for treatment of hypercholesterolemia)
 RN 287714-41-4 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



10/576,774 (formula 8)

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2007:1029750 CAPLUS
 DN 147:365510
 TI Dibenzyl amine compounds and derivatives as CETP inhibitors and their preparation, pharmaceutical compositions and use in the treatment of atherosclerosis and cardiovascular diseases
 IN Chang, George; Garigipati, Ravi S.; Lefker, Bruce; Perry, David A.
 PA Pfizer Inc, USA
 SO U.S. Pat. Appl. Publ., 124 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070213314	A1	20070913	US 2007-619299	20070103
	AU 2007226260	A1	20070920	AU 2007-226260	20070228
	CA 2645291	A1	20070920	CA 2007-2645291	20070228
	CA 2717242	A1	20070920	CA 2007-2717242	20070228
	WO 2007105049	A1	20070920	WO 2007-IB524	20070228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP	1994015	A1	20081126	EP 2007-705669	20070228
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	JP 2009529573	T	20090820	JP 2008-558923	20070228
	NL 2000527	A1	20070911	NL 2007-2000527	20070307
	NL 2000527	C2	20080206		
	AR 59802	A1	20080430	AR 2007-100979	20070309
	ZA 2008007106	A	20091125	ZA 2008-7106	20080818
	NO 2008003642	A	20080929	NO 2008-3642	20080822
	IN 2008DN07175	A	20081003	IN 2008-DN7175	20080822
	MX 2008011045	A	20080908	MX 2008-11045	20080828
	KR 2008093156	A	20081020	KR 2008-7022081	20080909
	CN 101437803	A	20090520	CN 2007-80016505	20081107
PRAI	US 2006-781488P	P	20060310		
	US 2007-619299	A	20070103		
	CA 2007-2645291	A3	20070228		
	WO 2007-IB524	W	20070228		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 147:365510

AB Dibenzyl amine compds. and derivs. of formula I, pharmaceutical compns. containing such compds. and the use of such compds. to elevate certain plasma lipid levels, including high d. lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by

low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans. Compds. of formula I wherein A is CO₂-C₁-4 alkyl, CN, CHO, CONH₂, etc.; B is NH₂ and derivs., and (un)substituted 3- to 8-membered heterocyclic ring; X is X and N, wherein if X is N, R₄ is absent; R₁, R₂, R₃, R₄, R₅, R₆ and R₇ are independently H, halo, CN, OH, NO₂, (un)substituted C₁-6 alkyl, etc.; and their pharmaceutically acceptable salts thereof are claimed. Example compound II was prepared by reductive amination of 2-[(3,5-bis(trifluoromethyl)benzyl)(2-methyl-2H-tetrazol-5-yl)amino]methyl]-4-trifluoromethylbenzaldehyde with dimethylamine. All the invention compds. were evaluated for their CETP inhibitory activity (no data).

IT 287714-41-4, Rosuvastatin


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(codrug; preparation of dibenzyl amine compds. and derivs. as CETP inhibitors and their use in the treatment of atherosclerosis and cardiovascular diseases)

RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L8 ANSWER 24 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2007:846111 CAPLUS
 DN 147:219926
 TI Manufacturing rosuvastatin potassium
 IN Patel, Dhimant Jasubhai; Kumar, Rajiv; Agarwal, Virendra Kumar
 PA Cadila Healthcare Limited, India
 SO PCT Int. Appl., 15 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007086082	A2	20070802	WO 2007-IN37	20070125
	WO 2007086082	A3	20070920		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	AU 2007208965	A1	20070802	AU 2007-208965	20070125
	EP 1979330	A2	20081015	EP 2007-736510	20070125
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	JP 2009530232	T	20090827	JP 2008-551959	20070125
	US 20100274014	A1	20101028	US 2010-161455	20100709
PRAI	IN 2006-MU1217	A	20060130		
	WO 2007-IN37	W	20070125		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 147:219926; MARPAT 147:219926

AB A process of manufacturing of Rosuvastatin potassium is disclosed. The process comprises the steps of treating Rosuvastatin protected compound (I) with an HCl and then KOH in methanol to form Rosuvastatin potassium and then isolation.


IT 860774-56-7P, Rosuvastatin potassium

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(manufacturing rosuvastatin potassium)

RN 860774-56-7 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, potassium salt (1:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



● K

L8 ANSWER 25 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2007:844109 CAPLUS
 DN 147:235189
 TI Process for preparation of statins with high syn to anti ratio
 IN Niddam-Hildesheim, Valerie; Balanov, Anna; Chen, Kobi
 PA Teva Pharmaceutical Industries Ltd., Israel
 SO U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 20,834.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070179166	A1	20070802	US 2006-520295	20060912
	CA 2645396	A1	20050714	CA 2004-2645396	20041223
	US 20050159615	A1	20050721	US 2004-20834	20041223
	JP 2008031168	A	20080214	JP 2007-191419	20070723
	US 20080269270	A1	20081030	US 2008-75848	20080313
	US 7851624	B2	20101214		
PRAI	US 2003-532458P	P	20031224		
	US 2004-547715P	P	20040224		
	US 2004-20834	A2	20041223		
	US 2005-716802P	P	20050912		
	CA 2004-2550742	A3	20041223		
	JP 2006-545612	A3	20041223		
	US 2006-520295	A2	20060912		
	US 2007-906914P	P	20070313		
	US 2007-918466P	P	20070315		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 147:235189; MARPAT 147:235189

AB Provided is a process for reduction of statin keto esters and purification of diol

esters of the statins through selective crystallization A process for preparing

rosuvastatin diol ester by reduction of I wherein R1 is (un)branched C1-4 alkyl; at least one of X is forms a double bond to give a ketone and at most one X is H; are claimed. Rosuvastatin diol ester I (R1 is t-Bu; X is H) was obtained by reduction of the keto ester derivative with B-methoxy-9-BBN

and


borohydride. High syn to anti ratio was obtained by crystallization of the diol.

IT 355806-00-7P
 RL: IMF (Industrial manufacture); PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
 (process for preparation of statins with high syn to anti ratio)

RN 355806-00-7 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, 1,1-dimethyl ester, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




IT 147098-20-2P, Rosuvastatin calcium

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for preparation of statins with high syn to anti ratio)

RN 147098-20-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



● 1/2 Ca

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L8 ANSWER 26 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2007:790313 CAPLUS
 DN 147:173649
 TI Combination of triazine derivatives and HMG-CoA reductase inhibitors
 IN Moinet, Gerard; Cravo, Daniel; Mesangeau, Didier
 PA Merck Patent GmbH, Germany
 SO PCT Int. Appl., 34pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007079916	A2	20070719	WO 2006-EP12184	20061218
	WO 2007079916	A3	20071206		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	FR 2896158	A1	20070720	FR 2006-343	20060113
	FR 2896158	B1	20080912		
	AU 2006334733	A1	20070719	AU 2006-334733	20061218
	CA 2636840	A1	20070719	CA 2006-2636840	20061218
	EP 1978951	A2	20081015	EP 2006-829705	20061218
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2009523141	T	20090618	JP 2008-549782	20061218
	AR 59031	A1	20080312	AR 2007-100137	20070112
	MX 2008008887	A	20080717	MX 2008-8887	20080709
	CN 101355935	A	20090128	CN 2006-80050848	20080710
	US 20100158999	A1	20100624	US 2008-160504	20080710
	KR 2008085208	A	20080923	KR 2008-7019392	20080807
	IN 2008KN03247	A	20090213	IN 2008-KN3247	20080807
	ZA 2008006937	A	20090729	ZA 2008-6937	20080812
PRAI	FR 2006-343	A	20060113		
	WO 2006-EP12184	W	20061218		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 147:173649

AB The present patent application relates to combinations of a triazine derivative with an HMG-CoA reductase inhibitor. Thus, a formulation contained pravastatin 10, and (+)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine-HCl 750 mg in addition to conventional excipients.

IT 287714-41-4, Rosuvastatin 944108-55-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(combination of triazine derivs. and HMG-CoA reductase inhibitors)

RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R, 5S, 6E)-

(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 944108-55-8 CAPLUS


CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-, mixt. with (+)-1,6-dihydro-N2,N2,6-trimethyl-1,3,5-triazine-2,4-diamine
 (CA INDEX NAME)

CM 1

CRN 775351-65-0

CMF C6 H13 N5

Absolute stereochemistry. Rotation (+).




CM 2

CRN 287714-41-4

CMF C22 H28 F N3 O6 S

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



L8 ANSWER 27 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2007:201603 CAPLUS
 DN 146:259000
 TI Pharmaceuticals containing a crystalline rosuvastatin intermediate
 IN Niddam-Hildesheim, Valerie; Shenkar, Natalia; Wizel, Shlomit
 PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
 SO PCT Int. Appl., 26pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007022488	A2	20070222	WO 2006-US32539	20060816
	WO 2007022488	A3	20070503		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	CA 2619576	A1	20070222	CA 2006-2619576	20060816
	US 20070123550	A1	20070531	US 2006-506030	20060816
	US 7868169	B2	20110111		
	EP 1805148	A2	20070711	EP 2006-801964	20060816
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	JP 2008515931	T	20080515	JP 2007-535928	20060816
	BR 2006005917	A2	20090526	BR 2006-5917	20060816
	MX 2007004427	A	20070614	MX 2007-4427	20070412
	KR 2007062996	A	20070618	KR 2007-7008332	20070412
	IN 2008DN01524	A	20080620	IN 2008-DN1524	20080221
	CN 101282944	A	20081008	CN 2006-80037309	20080407
PRAI	US 2005-708920P	P	20050816		
	US 2005-710930P	P	20050823		
	WO 2006-US32539	W	20060816		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 146:259000

AB Provided is a crystalline rosuvastatin intermediate and processes for preparation


thereof. The rosuvastatin intermediate was dissolved in MeOH-H₂O (5:1) under heating until homogenization. The solution was cooled and seeding was used. The solid was filtered and washed with MeOH-H₂O and dried at 50° to give the intermediate.

IT 287714-41-4P, Rosuvastatin

RL: SPN (Synthetic preparation); PREP (Preparation)
 (target compound; pharmaceuticals containing crystalline rosuvastatin intermediate)

RN 287714-41-4 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L8 ANSWER 28 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2006:1289954 CAPLUS

DN 146:81878

TI Method for synthesis of Rosuvastatin and its pivotal intermediates

IN Dai, Jian; Zhang, Yueliang; Xiang, Chunli; Huang, He

PA Sine Pharma Laboratory, Peop. Rep. China

SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 11pp.

CODEN: CNXXEV

DT Patent

LA Chinese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1872841	A	20061206	CN 2005-10026350	20050601
PRAI CN 2005-10026350		20050601		
OS CASREACT 146:81878				

AB The title method comprises the steps of: (1) reacting compound I with HF to obtain compound II; (2) extracting the reaction mixture with ether; (3) separating the organic phase, and vaporizing to remove the solvent and obtain concentrated solution containing compound II; (4) adding toluene/ether mixture and stirring at room temperature

till dissoln.; (5) cooling to 0-4° and completely crystallizing; (6) filtrating and drying in vacuum to obtain yellow crystals II.

In step 4, the W/V ratio of concentrated solution to toluene/ether mixture is 1:(1-1.5). The volume ratio of toluene/ether is (1-3):1. The method can obtain pure compound II, thus ensures the completeness of stereoselectivity in the sequential reactions. The method has the advantages of low synthesis cost, short synthesis period and high total efficiency.

IT 147118-40-9P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of Rosuvastatin and its intermediates)

RN 147118-40-9 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, methyl ester,
 (3R,5S,6E)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.



L8 ANSWER 29 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2006:1250227 CAPLUS
 DN 146:155299
 TI Structure-Based Rational Quest for Potential Novel Inhibitors of Human HMG-CoA Reductase by Combining CoMFA 3D QSAR Modeling and Virtual Screening
 AU Zhang, Qing Y.; Wan, Jian; Xu, Xin; Yang, Guang F.; Ren, Yan L.; Liu, Jun J.; Wang, Hui; Guo, Yu
 CS Key Laboratory of Pesticide and Chemical Biology (CCNU) of Ministry of Education, College of Chemistry, Central China Normal University, Wuhan, 430079, Peop. Rep. China
 SO Journal of Combinatorial Chemistry (2007) 9(1), 131-138
 CODEN: JCCHFF; ISSN: 1520-4766
 PB American Chemical Society
 DT Journal
 LA English
 AB 3-Hydroxy-3-methylglutaryl-CoA reductase (HMGR) catalyzes the formation of mevalonate. In many classes of organisms, this is the committed step leading to the synthesis of essential compds., such as cholesterol. However, a high level of cholesterol is an important risk factor for coronary heart disease, for which an effective clin. treatment is to block HMGR using inhibitors like statins. Recently the structures of catalytic portion of human HMGR complexed with six different statins have been determined by a delicate crystallog. study (Istvan and Deisenhofer Science 2001, 292, 1160-1164), which established a solid basis of structure and mechanism for the rational design, optimization, and development of even better HMGR inhibitors. In this study, three-dimensional quant. structure-activity relationship (3D QSAR) with comparative mol. field anal. (CoMFA) was performed on a training set of up to 35 statins and statin-like compds. Predictive models were established by using two different ways: (1) Models-fit, obtained by SYBYL conventional fit-atom mol. alignment rule, has cross-validated coeffs. (q2) up to 0.652 and regression coeffs. (r2) up to 0.977. (2) Models-dock, obtained by FlexE by docking compds. into the HMGR active site, has cross-validated coeffs. (q2) up to 0.731 and regression coeffs. (r2) up to 0.947. These models were further validated by an external testing set of 12 statins and statin-like compds. Integrated with CoMFA 3D QSAR predictive models, mol. surface property (electrostatic and steric) mapping and structure-based (both ligand and receptor) virtual screening have been employed to explore potential novel hits for the HMGR inhibitors. A representative set of eight new compds. of non-statin-like structures but with high pIC₅₀ values were sorted out in the present study.
 IT 287714-41-4, Rosuvastatin
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (SAR quest for potential inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening)
 RN 287714-41-4 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 30 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2006:768584 CAPLUS
 DN 145:188903
 TI Preparation of polymorphic crystalline forms of the
 antihypercholesteremic rosuvastatin calcium
 IN Blatter, Fritz; Van Der Schaaf, Paul Adriaan; Szelagiewicz, Martin
 PA Ciba Specialty Chemicals Holding Inc., Switz.
 SO PCT Int. Appl., 22pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006079611	A1	20060803	WO 2006-EP50351	20060123
	W: AE, AG, AL, AM, AT, AU, AZ	BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	CA 2594692	A1	20060803	CA 2006-2594692	20060123
	EP 1844021	A1	20071017	EP 2006-707784	20060123
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2008528542	T	20080731	JP 2007-552625	20060123
	US 20080194604	A1	20080814	US 2007-883008	20070725
PRAI	EP 2005-100598	A	20050131		
	WO 2006-EP50351	W	20060123		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB Polymorphic crystalline forms B and C of the antihypercholesteremic rosuvastatin calcium are prepared by dissolving rosuvastatin calcium in water containing an anionic surfactant, followed by precipitation and/or crystallization, are characterized, and claimed for use in human pharmaceutical dosage forms.

IT 147098-20-2, Rosuvastatin calcium
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (preparation of polymorphic crystalline forms of antihypercholesteremic rosuvastatin calcium)

RN 147098-20-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



● 1/2 Ca

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 31 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2006:316902 CAPLUS
 DN 144:376459
 TI Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
 IN Rafeeq, Mohammad; De, Shantanu; Sathyanarayana, Swargam; Kumar, Yatendra
 PA Ranbaxy Laboratories Limited, India
 SO PCT Int. Appl., 19 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006035277	A2	20060406	WO 2005-IB2784	20050920
	WO 2006035277	A3	20060803		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1797046	A2	20070620	EP 2005-797982	20050920
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	IN 2007DN03039	A	20070831	IN 2007-DN3039	20070423
	US 20080234302	A1	20080925	US 2008-575817	20080317
PRAI	IN 2004-DE1844	A	20040927		
	IN 2004-DE1845	A	20040927		
	WO 2005-IB2784	W	20050920		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Provided are processes for preparing amorphous rosuvastatin calcium from crystalline rosuvastatin calcium by simple crystallization processes. Also provided is


a novel polymorphic form of rosuvastatin sodium, processes for preparing thereof and pharmaceutical compns. thereof. Crystalline rosuvastatin calcium (20 g) was added to denatured spirit (40 mL) and the resultant mixture was stirred for 10 min at ambient temperature and then heated to about 77° to form produce a clear solution. The clear solution was immediately cooled to about 0° over 10 min. The resultant suspension was stirred at 0°C for 30 min. The separated product was filtered and dried under vacuum at about 40-45° to yield amorphous rosuvastatin calcium, yield: 1.3 g (65%), HPLC purity:99.72%.

IT 147098-18-8P, Rosuvastatin sodium 147098-20-2P,
 Rosuvastatin calcium 355805-96-8P
 RL: PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (novel processes for preparing amorphous rosuvastatin calcium and novel polymorphic form of rosuvastatin sodium)

RN 147098-18-8 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-

[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, sodium salt
(1:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




● Na

RN 147098-20-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt
(2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




● 1/2 Ca

RN 355805-96-8 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, compd. with methanamine (1:1), (3R,5S,6E)- (CA INDEX NAME)

CM 1

CRN 287714-41-4
 CMF C22 H28 F N3 O6 S

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




CM 2

CRN 74-89-5
 CMF C H5 N

H₃C—NH₂

IT 287714-41-4, Rosuvastatin
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (novel processes for preparing amorphous rosuvastatin calcium and novel polymorphic form of rosuvastatin sodium)
 RN 287714-41-4 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 32 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2006:300841 CAPLUS
 DN 144:363029
 TI Active Metabolite of Atorvastatin Inhibits Membrane Cholesterol Domain Formation by an Antioxidant Mechanism
 AU Mason, R. Preston; Walter, Mary F.; Day, Charles A.; Jacob, Robert F.
 CS Elucida Research, Beverly, MA, 01915-0011, USA
 SO Journal of Biological Chemistry (2006), 281(14), 9337-9345
 CODEN: JBCHA3; ISSN: 0021-9258
 PB American Society for Biochemistry and Molecular Biology
 DT Journal
 LA English
 AB The advanced atherosclerotic lesion is characterized by the formation of microscopic cholesterol crystals that contribute to mechanisms of inflammation and apoptotic cell death. These crystals develop from membrane cholesterol domains, a process that is accelerated under conditions of hyperlipidemia and oxidative stress. In this study, the comparative effects of hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors (statins) on oxidative stress-induced cholesterol domain formation were tested in model membranes containing physiol. levels of cholesterol using small angle x-ray diffraction approaches. In the absence of HMG-CoA reductase, only the atorvastatin active o-hydroxy metabolite (ATM) blocked membrane cholesterol domain formation as a function of oxidative stress. This effect of ATM is attributed to electron donation and proton stabilization mechanisms associated with its phenoxy group located in the membrane hydrocarbon core. ATM inhibited lipid peroxidn. in human low d. lipoprotein and phospholipid vesicles in a dose-dependent manner, unlike its parent and other statins (pravastatin, rosuvastatin, simvastatin). These findings indicate an atheroprotective effect of ATM on membrane lipid organization through a potent antioxidant mechanism.
 IT 287714-41-4, Rosuvastatin
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (active metabolite of atorvastatin inhibits membrane cholesterol domain formation by antioxidant mechanism)
 RN 287714-41-4 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



OSC.G 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 33 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2006:283969 CAPLUS
 DN 144:445353
 TI Use of statins and other immunomodulatory agents in treatment of autoimmune disease
 IN Garren, Hideki; Steinman, Lawrence
 PA Board of Trustees, Leland Stanford Junior University, USA; Bayhill Therapeutics, Inc.
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 66 pp.
 CODEN: CNXXEV

DT Patent
 LA Chinese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1652770	A	20050810	CN 2003-810847	20030331
PRAI	US 2002-368803	A	20020529		

AB Methods are provided for the treatment of autoimmune diseases, by co-administering a statin and a second immunomodulatory agent. The second immunomodulatory agent can be antigen-specific or non-antigen-specific. The statin is selected from rosuvastatin, mevastatin, lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, and cerivastatin. The antigen-specific immune regulator is selected from self-vector composed of polynucleotide and self-protein or self-peptide associated with the autoimmune disease containing amino acid sequence of autoantigenic epitope. The antigen-nonspecific immune regulator is an immune modulatory sequence selected from the groups consisting of (a) 5'-Purine-Pyrimidine-[X]-[Y]-Pyrimidine-Pyrimidine-3' and (b) 5'-Purine-Purine-[X]-[Y]-Pyrimidine-Pyrimidine-3', wherein X and Y are any naturally occurring or synthetic nucleotide, except cytosine-guanine.

IT 287714-41-4, Rosuvastatin
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of statins and other immunomodulatory agents in treatment of autoimmune disease)

RN 287714-41-4 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



L8 ANSWER 34 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

AN 2005:1126627 CAPLUS

DN 143:393062

TI Combinations comprising (S)-amlodipine and an HMG-CoA reductase inhibitor and/or cholesterol absorption inhibitor for reducing hypertension

IN Barberich, Timothy J.

PA Sepracor Inc., USA

SO PCT Int. Appl., 123 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005097191	A2	20051020	WO 2005-US9910	20050325
	WO 2005097191	A3	20051208		
		W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
		RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		

PRAI US 2004-559612P P 20040404

AB The present invention relates to pharmaceutical compns. comprising optically pure (S)-amlodipine and a HMG-CoA reductase inhibitor, preferably lovastatin. Another aspect of the present invention relates to a pharmaceutical composition comprising optically pure (S)-amlodipine and a cholesterol absorption inhibitor, preferably ezetimibe, or optically pure (S)-amlodipine, a HMG-CoA reductase inhibitor, and a cholesterol absorption inhibitor. The aforementioned pharmaceutical compns. further comprises niacin. The invention also relates to methods for treating a patient suffering from hypertension, hyperlipidemia, or a cardiac disorder. The invention also relates to methods for the treatment of hypertension and hyperlipidemia. For example, a solution of L-malic acid (6.68 kg, 49.82 mol) in isopropanol-water was added to a solution of (S)-amlodipine (19.5 kg, 47.69 mol) in isopropanol-MTBE and the reaction mixture was held with agitation for about one hour at about 50°C to form a slurry. The slurry was cooled with agitation to about 0° over 2.5 to 3 h and held with agitation at about 0° for about one hour. The solid product was isolated by filtration at about 0° and the wet cake obtained was dried at about 60° in vacuo to provide (S)-amlodipine L-malate (Form A) (25.41 kg, 46.79 mol, 98.1% yield). Tablets were prepared containing (S)-amlodipine L-malate (Form A) 3.32%, Avicel PH 101 70.7%, Starch 1500 20.75%, Explotab 5.0%, and magnesium stearate 0.25%.

IT 287714-41-4, Rosuvastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations comprising amlodipine and HMG-CoA reductase inhibitor and/or cholesterol absorption inhibitor for treatment of cardiovascular disorders)


RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-

10/576,774 (formula 8)

[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 35 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2005:902867 CAPLUS
 DN 143:229878
 TI Preparation of amorphous salts of rosuvastatin
 IN Kumar, Yatendra; Rafiq, Mohammad; De, Shantanu; Sathyanarayana, Swargam
 PA Ranbaxy Laboratories Limited, India
 SO PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005077917	A1	20050825	WO 2005-IB132	20050119
		W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
		RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG		
	EP 1737828	A1	20070103	EP 2005-702294	20050119
		R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR		
	IN 2006DN04805	A	20070831	IN 2006-DN4805	20060822
PRAI	IN 2004-DE77	A	20040119		
	WO 2005-IB132	W	20050119		

AB An amorphous crystalline form of rosuvastatin magnesium is described as is a process for its preparation from crystalline rosuvastatin magnesium, rosuvastatin Me ammonium salt, and from rosuvastatin lactone is described.


IT 355805-96-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (in the preparation of amorphous salts of rosuvastatin)

RN 355805-96-8 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, compd. with methanamine (1:1), (3R,5S,6E)- (CA INDEX NAME)

CM 1

CRN 287714-41-4
 CMF C22 H28 F N3 O6 S

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




CM 2

CRN 74-89-5
CMF C H5 N $\text{H}_3\text{C}-\text{NH}_2$

IT 147098-20-2P, Rosuvastatin calcium 355806-14-3P
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (preparation of amorphous salts of rosuvastatin)
 RN 147098-20-2 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




● 1/2 Ca

RN 355806-14-3 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, magnesium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



● 1/2 Mg

OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/576,774 (formula 8)

L8 ANSWER 36 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2005:673270 CAPLUS
 DN 143:172682
 TI A trans-salification method for the preparation of the rosuvastatin calcium from its potassium or sodium salt
 IN Sebek, Pavel; Radl, Stanislav; Stach, Jan
 PA Zentiva, A. S., Czech Rep.
 SO PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005068435	A1	20050728	WO 2004-CZ88	20041217
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1704144	A1	20060927	EP 2004-821059	20041217
	EP 1704144	B1	20070207	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU	
	US 20070155765	A1	20070705	US 2007-585933	20070104
PRAI	CZ 2004-86	A	20040116		
	WO 2004-CZ88	W	20041217		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 143:172682; MARPAT 143:172682

AB Rosuvastatin calcium is prepared by extracting an aqueous solution of the sodium or

potassium salt of rosuvastatin with an optional admixt. of sodium or potassium hydroxide or other sodium or potassium salts having inorg. anions with an organic solvent, incompletely miscible with water, selected from esters R₁CO₂R₂, ketones R₁COR₂, and alcs. R₁OH (R₁, R₂ = H, C₁-10 aliphatic hydrocarbyl, C₆ aryl, C₅-6 cyclic hydrocarbyl) the extract being subsequently shaken with an aqueous solution of an inorg. or C₁-5 organic calcium

salt, and the product is further isolated by cooling and/or adding an anti-solvent and filtration, and optionally, is converted into its amorphous form.

IT 147118-40-9, Rosuvastatin methyl ester

RL: RCT (Reactant); RACT (Reactant or reagent)


(saponification of; trans-salification method for the preparation of the rosuvastatin calcium from its potassium or sodium salt)

RN 147118-40-9 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, methyl ester, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 147098-20-2P, Rosuvastatin calcium


RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(trans-salification method for the preparation of the rosuvastatin calcium from its potassium or sodium salt)

RN 147098-20-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



● 1/2 Ca

IT 147098-18-8P, Rosuvastatin Sodium 860774-56-7P,
Rosuvastatin potassium


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(trans-salification method for the preparation of the rosuvastatin calcium from its potassium or sodium salt)

RN 147098-18-8 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-

[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, sodium salt (1:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




● Na

RN 860774-56-7 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, potassium salt (1:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



● K

10/576,774 (formula 8)

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 37 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2005:673108 CAPLUS
 DN 143:159611
 TI Pharmaceutical compositions comprising higher primary aliphatic alcohols and HMG CoA reductase inhibitor and process of preparation thereof
 IN Jindal, Kour Chand; Singh, Sukhjeet; Jain, Rajesh
 PA Panacea Biotec Ltd., India
 SO PCT Int. Appl., 30 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005067921	A1	20050728	WO 2005-IN24	20050119
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	IN 2004DE00099	A	20060210	IN 2004-DE99	20040120
	AU 2005205165	A1	20050728	AU 2005-205165	20050119
	AU 2005205165	B2	20080424		
	AU 2005205165	B9	20080911		
	CA 2553988	A1	20050728	CA 2005-2553988	20050119
	EP 1755587	A1	20070228	EP 2005-709165	20050119
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	ZA 2006009583	A	20080827	ZA 2006-9583	20050119
	MX 2006009500	A	20061107	MX 2006-9500	20060818
	US 20080247962	A1	20081009	US 2008-586545	20080612
PRAI	IN 2004-DE99	A	20040120		
	WO 2005-IN24	W	20050119		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A novel pharmaceutical composition comprising a mixture of higher primary aliphatic


alcs. from (24) to (39) carbon atoms; at least one other component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compds., and HMG CoA reductase inhibitor, its salts, analogs or derivs. thereof, preferably statins, optionally with pharmaceutically acceptable excipients, and process of preparation of such composition is provided. Also provided are a method of treatment and use of such composition for reducing abnormal lipid parameters associated with hyperlipidemia.

IT 287714-41-4, Rosuvastatin
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (pharmaceutical compns. comprising higher primary aliphatic alcs. and HMG CoA reductase inhibitor and process of preparation thereof)

RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 38 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2005:612271 CAPLUS
 DN 143:115390
 TI Process for preparation of statins with high syn to anti ratio
 IN Lifshitz-Liron, Revital; Perlman, Nurit
 PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
 SO PCT Int. Appl., 23 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005063728	A2	20050714	WO 2004-US43466	20041223
	WO 2005063728	A3	20060223		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2550742	A1	20050714	CA 2004-2550742	20041223
	CA 2645396	A1	20050714	CA 2004-2645396	20041223
	EP 1697338	A2	20060906	EP 2004-815531	20041223
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
	JP 2007520464	T	20070726	JP 2006-545612	20041223
	JP 4037900	B2	20080123		
	TW 258370	B	20060721	TW 2004-140548	20041224
	IN 2006DN02856	A	20070810	IN 2006-DN2856	20060519
	KR 2006135712	A	20061229	KR 2006-7014318	20060714
	JP 2008031168	A	20080214	JP 2007-191419	20070723
	KR 2009010126	A	20090128	KR 2008-7032136	20081230
PRAI	US 2003-532458P	P	20031224		
	US 2004-547715P	P	20040224		
	CA 2004-2550742	A3	20041223		
	JP 2006-545612	A3	20041223		
	WO 2004-US43466	W	20041223		
	KR 2006-7014318	A3	20060714		

OS CASREACT 143:115390; MARPAT 143:115390

AB A process was disclosed for reduction of statin ketoesters, such as RCH(Y)CH(OH)CH₂COCH₂CO₂R₁ [R = organic radical that is inert to redn and allows for inhibition of 3-hydroxy-3-methylglutaryl CoA; Y = H or forms a double bond with the R group; R₁ = alkyl] and purification of the corresponding syn-diol esters syn-RCH(Y)CH(OH)CH₂CH(OH)CH₂CO₂R₁ of the statins via selective crystallization. Thus, β-keto ester I (R₁ = CMe₃, R₂ = OH, R₃R₄ = O) was reduced using 9-methoxy-9-borabicyclo[3.3.1]nonane and sodium borohydride in methanol at -70° for 2 h followed by treatment with 30% H₂O₂ soln to give syn-diol ester I (R₁ = CMe₃, R₂ = R₃ = β-OH, R₄ = α-H) in 73% yield and 99.0:0.45 d.e. The syn-diol ester was

further purified by crystallization and subsequently treated with 47% NaOH to form

fluvastatin sodium salt I (R1 = Na, R2 = R3 = β -OH, R4 = α -H) in 87% yield.

IT 287714-41-4P, Rosuvastatin


RL: IMF (Industrial manufacture); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; process for preparation of statins with high syn to anti ratio via stereoselective ketone reduction)

RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 39 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2005:493592 CAPLUS
 DN 143:32342
 TI Preparation and purification of crystalline rosuvastatin ammonium salts and rosuvastatin calcium
 IN Niddam-Hildesheim, Valerie; Aronhime, Judith
 PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
 SO PCT Int. Appl., 28 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005051921	A1	20050609	WO 2004-US39469	20041124
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2546701	A1	20050609	CA 2004-2546701	20041124
	CA 2546701	C	20100727		
	US 20050131066	A1	20050616	US 2004-996483	20041124
	US 7777034	B2	20100817		
	EP 1601658	A1	20051207	EP 2004-812066	20041124
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
	CN 1906175	A	20070131	CN 2004-80040800	20041124
	IN 2006DN02567	A	20070810	IN 2006-DN2567	20060508
PRAI	US 2003-525128P	P	20031124		
	US 2004-534479P	P	20040105		
	WO 2004-US39469	W	20041124		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB Provided are alkyl ammonium crystalline salts of rosuvastatin that provide for purification of rosuvastatin and its pharmaceutically acceptable salts. A process for purifying rosuvastatin calcium includes (a) converting rosuvastatin calcium salt to rosuvastatin acid; (b) converting rosuvastatin acid to rosuvastatin isopropylammonium salt; (c) converting the isopropylammonium salt to rosuvastatin calcium.

IT 852820-97-4P
 RL: PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and purification of crystalline rosuvastatin ammonium salts and rosuvastatin calcium)


RN 852820-97-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-, compd. with 2-propanamine (1:1) (CA INDEX NAME)

CM 1

CRN 287714-41-4
CMF C22 H28 F N3 O6 SAbsolute stereochemistry. Rotation (+).
Double bond geometry as shown.

CM 2


CRN 75-31-0
CMF C3 H9 N

IT 852820-98-5P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and purification of crystalline rosuvastatin ammonium salts and
 rosuvastatin calcium)

RN 852820-98-5 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-
 [methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-,
 compd. with cyclohexanamine (1:1) (CA INDEX NAME)

CM 1


CRN 287714-41-4
CMF C22 H28 F N3 O6 SAbsolute stereochemistry. Rotation (+).
Double bond geometry as shown.



CM 2

CRN 108-91-8

CMF C6 H13 N




IT 147098-20-2P, Rosuvastatin calcium

RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation and purification of crystalline rosuvastatin ammonium salts and rosuvastatin calcium)

RN 147098-20-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




● 1/2 Ca

IT 287714-41-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and purification of crystalline rosuvastatin ammonium salts and rosuvastatin calcium)

RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-
(CA INDEX NAME)Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/576,774 (formula 8)

L8 ANSWER 40 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2005:409510 CAPLUS
 DN 142:463747
 TI Process for the manufacture of the calcium salt of rosuvastatin
 (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid and their crystalline intermediates
 IN Okada, Tetsuo; Horbury, John; Laffan, David Dermot Patrick
 PA Astrazeneca Uk Limited, UK; Shionogi & Company Limited
 SO PCT Int. Appl., 42 pp.
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

Applicant's

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005042522	A1	20050512	WO 2004-GB4481	20041022
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004285750	A1	20050512	AU 2004-285750	20041022
	AU 2004285750	B2	20080313		
	CA 2543358	A1	20050512	CA 2004-2543358	20041022
	EP 1682536	A1	20060726	EP 2004-768997	20041022
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004015681	A	20061219	BR 2004-15681	20041022
	CN 1898233	A	20070117	CN 2004-80038296	20041022
	JP 2007509119	T	20070412	JP 2006-536173	20041022
	NZ 547094	A	20090531	NZ 2004-547094	20041022
	RU 2372349	C2	20091110	RU 2006-117337	20041022
	CN 101654453	A	20100224	CN 2009-10128724	20041022
	EP 2272842	A1	20110112	EP 2010-183668	20041022
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK				
	ZA 2006003173	A	20070725	ZA 2006-3173	20060420
	IN 2006DN02189	A	20070615	IN 2006-DN2189	20060421
	IN 229351	A1	20090306		
	MX 2006004553	A	20061110	MX 2006-4553	20060424
	NO 2006002263	A	20060519	NO 2006-2263	20060519
	KR 2006132829	A	20061222	KR 2006-7010002	20060523
	US 20070255060	A1	20071101	US 2007-576774	20070316
	JP 2008024712	A	20080207	JP 2007-228620	20070904
	JP 2008044948	A	20080228	JP 2007-228621	20070904
	IN 2008DN06756	A	20081024	IN 2008-DN6756	20080805
PRAI	GB 2003-24791	A	20031024		
	CN 2004-80038296	A3	20041022		
	EP 2004-768997	A3	20041022		
	JP 2006-536173	A3	20041022		

WO 2004-GB4481 W 20041022
 IN 2006-DN2189 A3 20060421

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OS MARPAT 142:463747


AB A process for the manufacture of the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid (rosuvastatin), useful as an HMGCoA reductase inhibitor, from a compound of the formula I (A is an acetal or ketal protecting group, R is alkyl), via isolated crystalline compds. of the formula II (R1 = R, H, metal) and III is described. Crystalline intermediates of formulas I-III are also described.

IT 355806-00-7P 851440-21-6P 851443-04-4P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (process for manufacture of calcium salt of rosuvastatin, (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, and their crystalline intermediates)

RN 355806-00-7 CAPLUS


CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, 1,1-dimethylethyl ester, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



RN 851440-21-6 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, 1-methylethyl ester, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 851443-04-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, ethyl ester, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 147098-20-2P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (process for manufacture of calcium salt of rosuvastatin,
 (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, and their crystalline intermediates)

RN 147098-20-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



● 1/2 Ca

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 41 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2005:395284 CAPLUS
 DN 142:435814
 TI Preparation of amorphous rosuvastatin calcium
 IN Kumar, Yatendra; Rafiq, Mohammad; De, Shantanu; Sathyanarayana, Swargam
 PA Ranbaxy Laboratories Limited, India
 SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040134	A1	20050506	WO 2004-IB3487	20041022
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	IN 2003DE01304	A	20080801	IN 2003-DE1304	20031022
	EP 1678148	A1	20060712	EP 2004-791742	20041022
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1886383	A	20061227	CN 2004-80034855	20041022
	US 20070191318	A1	20070816	US 2006-576410	20060420
	IN 2006DN02696	A	20070803	IN 2006-DN2696	20060512
PRAI	IN 2003-DE1304	A	20031022		
	WO 2004-IB3487	W	20041022		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB The invention relates to the preparation of pure amorphous rosuvastatin calcium (I) and pharmaceutical compns. that include the pure amorphous rosuvastatin calcium. The invention also relates to use of said compns. for treating hyperlipidemia, hypercholesterolemia, and atherosclerosis. The amorphous form was prepared from the crystalline form.

IT 147098-20-2, Rosuvastatin calcium 287714-41-4,
 Rosuvastatin
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (amorphous rosuvastatin calcium)

RN 147098-20-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




● 1/2 Ca

RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



IT 355805-96-8

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);
USES (Uses)
(amorphous rosuvastatin calcium)

RN 355805-96-8 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, compd. with


10/576,774 (formula 8)

methanamine (1:1), (3R,5S,6E)- (CA INDEX NAME)

CM 1

CRN 287714-41-4
CMF C22 H28 F N3 O6 S

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



CM 2

CRN 74-89-5
CMF C H5 N

H₃C—NH₂

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 42 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2005:281798 CAPLUS
 DN 142:341836
 TI Polymorphic forms of a fluorophenylpyrimidine sulfonamide derivative
 antihyperlipemic agent
 IN Black, Simon Nicholas; Owens, Lianne; Taylor, Nigel Philip; Warren,
 Kenneth Edwin Herbert
 PA Astrazeneca Uk Limited, UK
 SO PCT Int'l Appl., 15 pp.
 CODEN: PIXXD2

common assignee

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005028450	A1	20050331	WO 2004-GB4133	20040917
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004274239	A1	20050331	AU 2004-274239	20040917
	AU 2004274239	B2	20081204		
	CA 2538756	A1	20050331	CA 2004-2538756	20040917
	EP 1663990	A1	20060607	EP 2004-768676	20040917
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1852899	A	20061025	CN 2004-80026824	20040917
	CN 100439342	C	20081203		
	BR 2004014499	A	20061114	BR 2004-14499	20040917
	JP 2007505879	T	20070315	JP 2006-526703	20040917
	NZ 546007	A	20081128	NZ 2004-546007	20040917
	IN 2006DN01319	A	20070810	IN 2006-DN1319	20060310
	MX 2006003052	A	20061017	MX 2006-3052	20060317
	US 20070105882	A1	20070510	US 2006-572635 [abn]	20060317
	NO 2006001324	A	20060404	NO 2006-1324	20060323
	KR 2007017970	A	20070213	KR 2006-7007212	20060414
	ZA 2006002263	A	20071128	ZA 2006-2263	20070317
PRAI	GB 2003-21827	A	20030918		
	WO 2004-GB4133	W	20040917		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Two new polymorphic forms of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid tris(hydroxymethyl)methylammonium salt (I), processes for making them and their use in the production of a pharmaceutical useful in the treatment of, inter alia, hypercholesterolemia, hyperlipoproteinemia and atherosclerosis are described.

IT 659737-21-0
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(polymorphic forms of a fluorophenylpyrimidine sulfonamide derivative
antihyperlipemic agent)

RN 659737-21-0 CAPLUS


CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (CA INDEX NAME)

CM 1

CRN 287714-41-4

CMF C22 H28 F N3 O6 S


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



CM 2

CRN 77-86-1

CMF C4 H11 N O3



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 43 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2005:238964 CAPLUS
 DN 142:322710
 TI Crystalline form of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt
 IN Booth, Rebecca Jane; Cittern, Peter Anthony; Crabb, Jeffrey Norman;
 Horbury, John; Jones, David Wyn Calvert
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SO PCT Int. Appl., 23 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

common assignee

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005023779	A1	20050317	WO 2004-GB3829	20040908
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004270467	A1	20050317	AU 2004-270467	20040908
	AU 2004270467	B2	20080821		
	CA 2537962	A1	20050317	CA 2004-2537962	20040908
	EP 1663989	A1	20060607	EP 2004-768376	20040908
	EP 1663989	B1	20090415		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004014236	A	20061031	BR 2004-14236	20040908
	CN 1878760	A	20061213	CN 2004-80030826	20040908
	JP 2007505090	T	20070308	JP 2006-525882	20040908
	AT 428701	T	20090515	AT 2004-768376	20040908
	PT 1663989	E	20090609	PT 2004-768376	20040908
	ES 2324042	T3	20090729	ES 2004-768376	20040908
	RU 2363697	C2	20090810	RU 2006-111354	20040908
	NZ 545785	A	20100326	NZ 2004-545785	20040908
	IN 2006DN01213	A	20070713	IN 2006-DN1213	20060307
	US 20060293355	A1	20061228	US 2006-571254 abn	20060309
	ZA 2006002009	A	20070627	ZA 2006-2009	20060309
	MX 2006002761	A	20061214	MX 2006-2761	20060310
	KR 2007019943	A	20070216	KR 2006-7004952	20060310
	NO 2006001181	A	20060329	NO 2006-1181	20060314
	HK 1090361	A1	20090911	HK 2006-110818	20060928
	US 20100222373	A1	20100902	US 2009-615935	20091110
PRAI	GB 2003-21127	A	20030910		
	GB 2004-4859	A	20040304		
	WO 2004-GB3829	W	20040908		
	US 2006-571254	B1	20060309		


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Two polymorphic forms of I, processes for making them and their use as HMG

Co-A reductase inhibitors are described. I was prepared from the corresponding methlamine and Na salts.

IT 147098-20-2P 848029-33-4P
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (crystalline form of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt)
 RN 147098-20-2 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



●1/2 Ca

RN 848029-33-4 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt, hydrate (2:1?), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



● 1/2 Ca

IT 355805-96-8

RL: RCT (Reactant); RACT (Reactant or reagent)
 (crystalline form of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt)

RN 355805-96-8 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, compd. with methanamine (1:1), (3R,5S,6E)- (CA INDEX NAME)


CM 1

CRN 287714-41-4

CMF C22 H28 F N3 O6 S

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



CM 2

CRN 74-89-5

CMF C H5 N

H₃C—NH₂

IT 848029-34-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (crystalline form of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt)

RN 848029-34-5 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, sodium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.




● 1/2 Na

OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 44 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2005:99351 CAPLUS
 DN 142:170070
 TI Methods for treating inflammation and inflammation-associated diseases with a statin and ether
 IN Ghazzi, Maha Maria; Hartman, Daniel Lawrence
 PA Warner-Lambert Company LLC, USA
 SO PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005009431	A1	20050203	WO 2004-IB2451	20040719
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050026979	A1	20050203	US 2004-872023	20040618
	CA 2534178	A1	20050203	CA 2004-2534178	20040719
	EP 1651205	A1	20060503	EP 2004-744104	20040719
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004013083	A	20061003	BR 2004-13083	20040719
	JP 2007500690	T	20070118	JP 2006-521701	20040719
	MX 2006001286	A	20060411	MX 2006-1286	20060131
PRAI	US 2003-492076P	P	20030731		
	WO 2004-IB2451	W	20040719		
OS	MARPAT 142:170070				
AB	Disclosed herein are methods for treating and preventing inflammation and inflammation-associated diseases by co-administering to a patient in need thereof a dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted-alkyl, or a pharmaceutically acceptable salt of said dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl, and a statin, or a pharmaceutically acceptable salt of said statin.				
IT	287714-41-4, Rosuvastatin RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (methods for treating inflammation and inflammation-associated diseases with a statin and ether combination)				
RN	287714-41-4 CAPLUS				
CN	6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(CA INDEX NAME)				


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 45 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2005:86402 CAPLUS
 DN 142:232346
 TI Molecular docking of the highly hypolipidemic agent α -asarone with the catalytic portion of HMG-CoA reductase
 AU Medina-Franco, Jose Luis; Lopez-Vallejo, Fabian; Rodriguez-Morales, Sergio; Castillo, Rafael; Chamorro, German; Tamariz, Joaquin
 CS Departamento de Farmacia, Facultad de Quimica, Universidad Nacional Autonoma de Mexico, Circuito Exterior, Ciudad Universitaria, D.F., 04510, Mex.
 SO Bioorganic & Medicinal Chemistry Letters (2005), 15(4), 989-994
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 AB Docking expts. using a number of published crystal structures of HMG-CoA reductase with the potent hypocholesterolemic agent α -asarone are described. The results indicate that α -asarone binds in the enzyme's active site. The methoxy groups play a key role in the binding and probably also in its biol. activity, as shown by extensive SAR studies reported for analogs of α -asarone. The docking results will be valuable for the structure-based design of novel hypolipidemic agents.
 IT 287714-41-4, Rosuvastatin
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (mol. docking of highly hypolipidemic agent α -asarone with HMG-CoA reductase)
 RN 287714-41-4 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/576,774 (formula 8)

L8 ANSWER 46 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2004:270120 CAPLUS
 DN 140:302423
 TI Chemoenzymatic methods for the synthesis of statins and stain intermediates
 IN Greenberg, William; Wong, Kelvin; Varvak, Alexander; Swanson, Ronald V.
 PA Diversa Corporation, USA
 SO PCT Int. Appl., 199 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004027075	A2	20040401	WO 2003-US27334	20030819
	WO 2004027075	A3	20071018		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA				
	AU 2003263031	A1	20040408	AU 2003-263031	20030819
	EP 1625223	A2	20060215	EP 2003-797874	20030819
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
	JP 2006512086	T	20060413	JP 2004-568922	20030819
	US 20050153407	A1	20050714	US 2004-472157	20040709
	US 7414119	B2	20080819		
	IN 2005MN00301	A	20051021	IN 2005-MN301	20050419
	IN 235510	A1	20090911		
	US 20080289056	A1	20081120	US 2008-32337	20080215
	IN 2009KN00533	A	20090515	IN 2009-KN533	20090209
PRAI	US 2002-412625P	P	20020920		
	US 2003-469374P	P	20030509		
	WO 2003-US27334	W	20030819		
	US 2004-472157	A3	20040709		
	IN 2005-MN301	A3	20050419		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention provides novel aldolases, nucleic acids encoding them and methods for making and using them, including chemoenzymic processes for making β,δ -dihydroxyheptanoic acid side chains and compns. comprising these side chains, e.g., $[[R-(R^*, R^*)]-2-(4-fluorophenyl)-\beta, \delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-(phenylamino)carbonyl]-1H-pyrrole-L-heptanoic acid (atorvastatin, (LIPITORTM), rosuvastatin (CRESTORTM), fluvastatin (LESCOLTM)), related compds. and their intermediates.


IT 147098-20-2P, CRESTOR
 RL: IMF (Industrial manufacture); PREP (Preparation)
 (chemoenzymic methods for synthesis of statins and stain intermediates)

RN 147098-20-2 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-

10/576,774 (formula 8)

[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt
(2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



● 1/2 Ca

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L8 ANSWER 47 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2003:897412 CAPLUS
 DN 140:120212
 TI Sodium (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-6-heptenate crystal form

AU Anon.
 CS USA
 SO IP.com Journal (2003), 3(9), 27-28 (No. IPCOM000019022D), 27 Aug 2003
 CODEN: IJPOBX; ISSN: 1533-0001
 PB IP.com, Inc.
 DT Journal; Patent
 LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI IP 19022D		20030827	IP 2003-19022D	20030827
PRAI IP 2003-19022D		20030827		

AB The x-ray powder diffraction patterns of 2 samples of the title compound are given.


IT 147098-18-8

RL: PRP (Properties)
 (x-ray powder diffraction data for)

RN 147098-18-8 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, sodium salt (1:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



● Na


L8 ANSWER 48 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2003:796474 CAPLUS
 DN 139:302035
 TI Use of statins and other immunomodulatory agents in the treatment of autoimmune disease
 IN Garren, Hideki; Steinman, Lawrence
 PA The Board of Trustees of the Leland Stanford Junior University, USA;
 Bayhill Therapeutics, Inc.
 SO PCT Int. Appl., 90 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003082269	A1	20031009	WO 2003-US9807	20030331
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2480634	A1	20031009	CA 2003-2480634	20030331
	AU 2003230765	A1	20031013	AU 2003-230765	20030331
	US 20030229044	A1	20031211	US 2003-404679	20030331
	US 20040002537	A1	20040101	US 2003-404922	20030331
	EP 1494665	A1	20050112	EP 2003-723858	20030331
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005527553	T	20050915	JP 2003-579807	20030331
PRAI	US 2002-368803P	P	20020329		
	WO 2003-US9807	W	20030331		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods are provided for the treatment of autoimmune diseases, by co-administering a statin and a second immunomodulatory agent. The second immunomodulatory agent can be antigen-specific or non-antigen-specific.
 IT 287714-41-4, Rosuvastatin
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of statins and other immunomodulatory agents in treatment of autoimmune disease)
 RN 287714-41-4 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 49 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2003:419137 CAPLUS
 DN 139:374715
 TI Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin
 AU Holdgate, G. A.; Ward, W. H. J.; McTaggart, F.
 CS AstraZeneca, Alderley Park, Cheshire, Macclesfield, Mereside, SK10 4TG, UK
 SO Biochemical Society Transactions (2003), 31(3), 528-531
 CODEN: BCSTB5; ISSN: 0300-5127
 PB Portland Press Ltd.
 DT Journal
 LA English
 AB The statins are inhibitors of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase (HMG-CoAR), and are utilized to decrease levels of atherogenic lipoproteins in patients with, or who are at high risk of, cardiovascular disease. This study describes the inhibition of a recombinant, catalytic fragment of human HMG-CoAR by a new statin, rosuvastatin (CRESTOR). Binding is reversible and involves an initial complex [inhibition constant involving the enzyme-inhibitor complex (E.I), $K_i \approx 1$ nM], which undergoes a slow transition ($t_{1/2}$ to reach steady state is 33-360 s) to give tighter association [steady-state inhibition constant involving E.I and the second E.I complex in a two-step mechanism (E.I*), $K_{i^*} \approx 0.1$ nM]. At steady state, rosuvastatin is at least as potent as atorvastatin, cerivastatin and simvastatin. It is more potent than fluvastatin and pravastatin. For rosuvastatin, inhibition kinetics are competitive with respect to HMG-CoA and non-competitive when NADPH is varied. At 37°, binding is linked to a large favorable enthalpy change [$\Delta H^\circ = -69.0$ kJ/mol (-16.5 kcal/mol)] and a small entropic penalty [$T \Delta S^\circ = -9.6$ kJ/mol (-2.3 kcal/mol)]. These characteristics, and the high affinity relative to that of 3 S -HMG-CoA ($K_d \approx 6.6$ μM), are discussed in relation to the crystal structures of complexes with HMG-CoAR.
 IT 287714-41-4, Rosuvastatin
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
 (mol. mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin)
 RN 287714-41-4 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



OSC.G 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)
RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 50 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2003:311198 CAPLUS
 DN 140:4
 TI Statin inhibition of HMG-CoA reductase: a 3-dimensional view
 AU Istvan, Eva
 CS Howard Hughes Medical Institute, Department of Molecular Microbiology,
 Washington University School of Medicine, St. Louis, MO, 63110, USA
 SO Atherosclerosis Supplements (2003), 4(1), 3-8
 CODEN: ASTUCD; ISSN: 1567-5688
 PB Elsevier Science Ireland Ltd.
 DT Journal; General Review
 LA English
 AB A review. Statins act by inhibiting 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase and thereby reducing cholesterol synthesis. In x-ray crystallog. studies, we have determined the structures of the catalytic portions of the enzyme in complex with statin mols. These studies show that the HMG-like moiety of statin mols. occupy the HMG binding site of the enzyme, with the hydrophobic groups of the statins occupying a binding site exposed by movement of flexible helixes in the enzyme catalytic domain. In addition to bonds formed by the HMG-like moiety, statins exhibit different types and nos. of binding interactions in association with structural differences. Type 1 statins (e.g., simvastatin) exhibit binding via a decalin ring structure, and type 2 statins (e.g., rosuvastatin, atorvastatin, fluvastatin) exhibit addnl. binding via their fluorophenyl group. Rosuvastatin and atorvastatin exhibit hydrogen bonds absent from other type 2 statins; rosuvastatin exhibits a unique bond via its electroneg. sulfone group. Differences in statin structure and binding characteristics may partially contribute to differences in potency of HMG-CoA reductase inhibition and other pharmacol. properties.
 IT 287714-41-4, Rosuvastatin
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (binding interactions of HMG-CoA reductase inhibitors)
 RN 287714-41-4 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



OSC.G 34 THERE ARE 34 CAPLUS RECORDS THAT CITE THIS RECORD (34 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 51 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2002:813874 CAPLUS
 DN 137:311199
 TI Amino acid complexes of C-aryl glucosides for treatment of diabetes
 IN Gougoutas, Jack Z.
 PA Bristol-Myers Squibb Company, USA
 SO PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002083066	A2	20021024	WO 2002-US11066	20020408
	WO 2002083066	A3	20030306		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2444481	A1	20021024	CA 2002-2444481	20020408
	AU 2002254567	A1	20021028	AU 2002-254567	20020408
	AU 2002254567	B2	20071011		
	US 20030064935	A1	20030403	US 2002-117914	20020408
	US 6774112	B2	20040810		
	EP 1385856	A2	20040204	EP 2002-723801	20020408
	EP 1385856	B1	20060222		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004536047	T	20041202	JP 2002-580871	20020408
	AT 318272	T	20060315	AT 2002-723801	20020408
	ES 2258141	T3	20060816	ES 2002-723801	20020408
	HU 2006000232	A2	20060828	HU 2006-232	20020408
	AU 2008200159	A1	20080207	AU 2008-200159	20080111
PRAI	US 2001-283097P	P	20010411		
	AU 2002-254567	A3	20020408		
	WO 2002-US11066	W	20020408		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 137:311199

AB Crystalline complexes are obtained from 1:1 or 2:1 mixts. of either the (D) or (L) enantiomer of natural amino acids and compds. of formula I [R1, R2, R2a = H, OH, OR5, alkyl, OCHF2, OCF3, SR5a, halogen; R3, R4 = H, OH, OR5b, alkyl, cycloalkyl, CF3, OCHF2, OCF3, halogen, CONR6R6a, CO2R5c, CO2H, COR6b, CH(OH)R6c, CH(OR5d)R6d, CN, NHCOR5e, NHSO2R5f, NHSO2-aryl, SR5g, SOR5h, SO2R5i, or a five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms (N, O, S, SO, and/or SO2), or R3 and R4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring; R5, R5a-R5i are independently alkyl; R6, R6a-R6d are independently H, alkyl, aryl, alkylaryl or cycloalkyl, or NR6R6a form an annelated five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring]. A method is also provided for treating diabetes and related diseases employing an SGLT2 (sodium


dependent glucose transporters found in the intestine and kidney) inhibiting amount of the above complex alone or in combination with another antidiabetic agent or other therapeutic agent. Thus, I (R1 = 4-Me, R4 = 4-OCHF₂, R₂, R_{2a}, R₃ = H) was prepared by a multistep procedure starting from o-toluic acid, anisole, 2,3,4,6-tetra-O-benzyl-β-D-glucolactone, and CHF₂Cl and treated with L-phenylalanine to form the crystalline 1:1 complex.

IT 287714-41-4, Rosuvastatin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of amino acid/C-aryl glucoside complexes for treatment of diabetes and related diseases)

RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



OSC.G 21 THERE ARE 21 CAPLUS RECORDS THAT CITE THIS RECORD (31 CITINGS)
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 52 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2002:575765 CAPLUS
 DN 137:140435
 TI Benzopyrancarboxylic acid derivatives with PPAR agonist activity for the treatment of diabetes and lipid disorders, and their preparation, pharmaceutical compositions, and use
 IN Sahoo, Soumya P.; Koyama, Hiroo; Miller, Daniel J.; Boueres, Julia K.; Desai, Ranjit C.
 PA Merck & Co., Inc., USA
 SO U.S. Pat. Appl. Publ., 42 pp.
 CODEN: USXXCO

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20020103242	A1	20020801	US 2001-21667	20011029
	US 6713508	B2	20040330		
	CA 2427610	A1	20020808	CA 2001-2427610	20011026
	WO 2002060434	A2	20020808	WO 2001-US49501	20011026
	WO 2002060434	A3	20030619		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002248221	A1	20020812	AU 2002-248221	20011026
	AU 2002248221	B2	20060817		
	EP 1347755	A2	20031001	EP 2001-997102	20011026
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004517938	T	20040617	JP 2002-560626	20011026
	JP 4350946	B2	20091028		
PRAI	US 2000-244698P	P	20001031		
	WO 2001-US49501	W	20011026		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 137:140435

AB A class of benzopyrancarboxylic acid derivs. is disclosed, which comprises compds. that are potent agonists (no data) of peroxisome proliferator activated receptors (PPAR) alpha and/or gamma, and are therefore useful in the treatment, control, or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions. In particular, compds. I and their pharmaceutically acceptable salts and/or prodrugs are disclosed [wherein: Z = CH₂, CO; R₁ = H, OH, halo, (un)substituted alk(en/yn)yl, alk(en/yn)yloxy, or aryl; or R₁ forms (un)substituted cyclopropane fusion to adjacent C atom; X, Y = O, S, SO, SO₂, CH₂, (un)substituted NH; n = 1-6; R₄ = (un)substituted benzoheterocyclyl, cycloalkyl, heterocyclyl, cycloalkyloxy, halo, OH or derivs., alk(en/yn)yl, alk(en/yn)yloxy, or aryl, etc.; other R groups = H, halo, OH, (un)substituted alk(en/yn)yl,

alk(en/yn)yloxy, aryl, aryloxy, aroyl, etc.; or R3R4 or R4R5 = (un)substituted 5- or 6-membered heterocyclic ring]. A list of 29 compds. is claimed, and their preparation is described. For example, Et 7-hydroxy-4-oxo-4H-chromene-2-carboxylate underwent a sequence of: (1) complete hydrogenation of the enone (98%), (2) etherification of the alc. with PhCH₂O(CH₂)₃Br (66%), (3) alpha ethylation of the ester (70%), (4) hydrogenolytic debenzylation (100%), (5) conversion of the resultant alc. to a bromide (96%), (6) etherification of the bromide with 3-(trifluoromethyl)-7-propyl-6-hydroxybenz[4,5]isoxazole (85%), and (7) alkaline hydrolysis (100%), to give title compound II. PPAR binding assays using human recombinant PPAR are described without data.

Co-administration of compds. I with a variety of other drug categories, including a number of specific drugs, is claimed.

IT 147098-20-2, ZD-4522


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic compns. also containing; preparation of benzopyrancarboxylic acid

derivs. as PPAR agonists for treatment of diabetes and lipid disorders)

RN 147098-20-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



●1/2 Ca

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L8 ANSWER 53 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2001:617984 CAPLUS
 DN 135:183499
 TI Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
 IN Taylor, Nigel Philip; Okada, Tetsuo
 PA Astrazeneca Ab, Swed.; Astrazeneca Uk Limited; Shionogi & Co., Ltd.
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060804	A1	20010823	WO 2001-GB574	20010212
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
	CA 2397450	A1	20010823	CA 2001-2397450	20010212
	CA 2397450	C	20091117		
	EP 1263739	A1	20021211	EP 2001-904167	20010212
	EP 1263739	B1	20080102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001008378	A	20030311	BR 2001-8378	20010212
	HU 2002004051	A2	20030528	HU 2002-4051	20010212
	HU 2002004051	A3	20030728		
	JP 2003523334	T	20030805	JP 2001-560189	20010212
	JP 4099333	B2	20080611		
	EE 2002000445	A	20031215	EE 2002-445	20010212
	EE 5288	B1	20100415		
	NZ 520032	A	20040326	NZ 2001-520032	20010212
	AU 775569	B2	20040805	AU 2001-32084	20010212
	CN 1210266	C	20050713	CN 2001-805027	20010212
	RU 2265599	C2	20051210	RU 2002-124621	20010212
	IL 150807	A	20070704	IL 2001-150807	20010212
	EP 1873148	A1	20080102	EP 2007-118593	20010212
	EP 1873148	B1	20091118		
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, LT, LV, MK, RO, SI				
	AT 382610	T	20080115	AT 2001-904167	20010212
	PT 1263739	E	20080219	PT 2001-904167	20010212
	ES 2298214	T3	20080516	ES 2001-904167	20010212
	AT 449079	T	20091215	AT 2007-118593	20010212
	SK 287144	B6	20100107	SK 2002-1174	20010212
	PT 1873148	E	20100120	PT 2007-118593	20010212
	ES 2335542	T3	20100329	ES 2007-118593	20010212
	PL 206729	B1	20100930	PL 2001-356472	20010212
	CZ 302136	B6	20101110	CZ 2002-2754	20010212
	ZA 2002005331	A	20031003	ZA 2002-5331	20020703

IN 2002MN00922	A	20050318	IN 2002-MN922	20020709
BG 106969	A	20030430	BG 2002-106969	20020731
BG 65562	B1	20081230		
MX 2002007819	A	20040910	MX 2002-7819	20020813
NO 2002003853	A	20020814	NO 2002-3853	20020814
NO 323770	B1	20070702		
US 20030045718	A1	20030306	US 2002-203890	20020815
US 6841554	B2	20050111		
HK 1051532	A1	20080620	HK 2003-103705	20030526
HK 1055958	A1	20060106	HK 2003-108229	20031112
US 20060014766	A1	20060119	US 2004-985019	20041110
US 7129352	B2	20061031		
PH 1200600339	A	20080915	PH 2006-1200600339	20060707
PRAI GB 2000-3305	A	20000215		
EP 2001-904167	A3	20010212		
WO 2001-GB574	W	20010212		
PH 2001-1200100329	A3	20010215		
US 2002-203890	A1	20020815		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to crystalline salts of the compound
 (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
 [methyl(methylsulfonyl)amino]pyrimidin-5
 yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid (I), as well as processes for
 their manufacture, pharmaceutical compns. containing them, and their uses.

Crystalline

salts of I and its derivs. can generally be purified more easily than
 amorphous or powdery forms and unlike them do not cause manufacturing problems.
 Methylamine was reacted with I (preparation given) to obtain methylammnium
 salt. The X-ray powder diffraction spectra of the methylammnium salt is
 presented.

IT 287714-41-4P 355806-00-7P 355806-03-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of crystalline salts of fluorophenyl aminopyrimidine heptenoic
 acid


derivs.)

RN 287714-41-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-
 [methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


Double bond geometry as shown.



RN 355806-00-7 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, 1,1-dimethylethyl ester, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 355806-03-0 CAPLUS

CN Methanaminium, 1-hydroxy-N,N-bis(hydroxymethyl)-N-methyl-, (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-6-heptenoate (1:1) (CA INDEX NAME)


CM 1

CRN 355806-02-9

CMF C22 H27 F N3 O6 S


Absolute stereochemistry.

Double bond geometry as shown.




CM 2

CRN 14433-29-5
CMF C4 H12 N O3



IT 147098-18-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
 USES (Uses)
 (preparation of crystalline salts of fluorophenyl aminopyrimidine heptenoic
 acid
 derivs.)
 RN 147098-18-8 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-
 [methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, sodium salt
 (1:1), (3R,5S,6E)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



● Na

IT 147098-20-2P 355805-96-8P 355806-04-1P
 355806-06-3P 355806-08-5P 355806-10-9P
 355806-11-0P 355806-13-2P 355806-14-3P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of crystalline salts of fluorophenyl aminopyrimidine heptenoic acid
 derivs.)
 RN 147098-20-2 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



● 1/2 Ca

RN 355805-96-8 CAPLUS


CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, compd. with methanamine (1:1), (3R,5S,6E)- (CA INDEX NAME)

CM 1

CRN 287714-41-4

CMF C22 H28 F N3 O6 S

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



CM 2

CRN 74-89-5
 CMF C H5 N


H₃C—NH₂

RN 355806-04-1 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 287714-41-4
 CMF C22 H28 F N3 O6 S

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




CM 2

CRN 111-42-2
 CMF C4 H11 N O2

HO—CH₂—CH₂—NH—CH₂—CH₂—OH

RN 355806-06-3 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, ammonium salt (1:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.




● NH₃

RN 355806-08-5 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, lithium salt (1:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




● Li

RN 355806-10-9 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, compd. with ethanamine (1:1), (3R,5S,6E)- (CA INDEX NAME)

CM 1


CRN 287714-41-4
CMF C22 H28 F N3 O6 SAbsolute stereochemistry. Rotation (+).
Double bond geometry as shown.

CM 2

CRN 75-04-7
CMF C2 H7 N $\text{H}_3\text{C}-\text{CH}_2-\text{NH}_2$ RN 355806-11-0 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, compd. with benzenemethanamine (1:1), (3R,5S,6E)- (CA INDEX NAME)

CM 1

CRN 287714-41-4
CMF C22 H28 F N3 O6 SAbsolute stereochemistry. Rotation (+).
Double bond geometry as shown.




CM 2

CRN 100-46-9
CMF C7 H9 N $\text{H}_2\text{N}-\text{CH}_2-\text{Ph}$ RN 355806-13-2 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-, compd. with 4-methoxybenzenemethanamine (1:1) (CA INDEX NAME)

CM 1


CRN 287714-41-4
CMF C22 H28 F N3 O6 SAbsolute stereochemistry. Rotation (+).
Double bond geometry as shown.



CM 2

CRN 2393-23-9


CMF C8 H11 N O



RN 355806-14-3 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, magnesium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




● 1/2 Mg

OSC.G 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 54 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2001:364374 CAPLUS
 DN 135:147214
 TI Structural mechanism for statin inhibition of HMG-CoA reductase
 AU Istvan, Eva S.; Deisenhofer, Johann
 CS Department of Biochemistry, University of Texas Southwestern medical
 Center at Dallas, TX, 75390-9050, USA
 SO Science (Washington, DC, United States) (2001), 292(5519), 1160-1164
 CODEN: SCIEAS; ISSN: 0036-8075
 PB American Association for the Advancement of Science
 DT Journal
 LA English
 AB HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase (HMGR) catalyzes the committed step in cholesterol biosynthesis. Statins are HMGR inhibitors with inhibition constant values in the nanomolar range that effectively lower serum cholesterol levels and are widely prescribed in the treatment of hypercholesterolemia. We have determined structures of the catalytic portion of human HMGR complexed with six different statins. The statins occupy a portion of the binding site of HMG-CoA, thus blocking access of this substrate to the active site. Near the carboxyl terminus of HMGR, several catalytically relevant residues are disordered in the enzyme-statin complexes. If these residues were not flexible, they would sterically hinder statin binding.
 IT 287714-41-4
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (structural mechanism for statin inhibition of HMG-CoA reductase)
 RN 287714-41-4 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



OSC.G 288 THERE ARE 288 CAPLUS RECORDS THAT CITE THIS RECORD (289 CITINGS)
 RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/576,774 (formula 8)

L8 ANSWER 55 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 AN 2000:493528 CAPLUS
 DN 133:125290
 TI Crystalline bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt
 IN Taylor, Nigel Phillip
 PA AstraZeneca UK Limited, UK
 SO PCT Int. Appl., 14 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000042024	A1	20000720	WO 1999-GB4439	19991223
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA	2356212	A1	20000720	CA 1999-2356212	19991223
CA	2356212	C	20090804		
BR	9916786	A	20011016	BR 1999-16786	19991223
EP	1144389	A1	20011017	EP 1999-962471	19991223
EP	1144389	B1	20041110		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR	2001001894	T2	20011221	TR 2001-1894	19991223
HU	2001004828	A2	20020729	HU 2001-4828	19991223
HU	2001004828	A3	20021028		
JP	2002539078	T	20021119	JP 2000-593592	19991223
EE	2001000359	A	20021216	EE 2001-359	19991223
EE	5033	B1	20080616		
AU	762909	B2	20030710	AU 2000-18826	19991223
NZ	512560	A	20030829	NZ 1999-512560	19991223
RU	2236404	C2	20040920	RU 2001-122164	19991223
AT	282027	T	20041115	AT 1999-962471	19991223
PT	1144389	E	20050228	PT 1999-962471	19991223
ES	2232194	T3	20050516	ES 1999-962471	19991223
CN	1213033	C	20050803	CN 1999-815504	19991223
IL	143977	A	20060221	IL 1999-143977	19991223
SK	285807	B6	20070802	SK 2001-963	19991223
CZ	299843	B6	20081210	CZ 2001-2460	19991223
PL	201800	B1	20090529	PL 1999-348775	19991223
ZA	2001005187	A	20020923	ZA 2001-5187	20010622
IN	2001MN00758	A	20050617	IN 2001-MN758	20010622
US	6589959	B1	20030708	US 2001-869462	20010628
NO	2001003368	A	20010905	NO 2001-3368	20010706
NO	320189	B1	20051107		
MX	2001006953	A	20011001	MX 2001-6953	20010706
HK	1040989	A1	20050506	HK 2002-102104	20020319
IN	2003MN00223	A	20050304	IN 2003-MN223	20030214
US	20040009997	A1	20040115	US 2003-410650	20030410

JP 2010090128	A 20100422	JP 2009-260812	20091116
PRAI GB 1999-339	A 19990109		
JP 2000-593592	A3 19991223		
WO 1999-GB4439	W 19991223		
IN 2001-MN758	A3 20010622		
US 2001-869462	A3 20010628		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to a crystalline form of I, as well as processes for its manufacture and pharmaceutical compns. comprising the crystalline form, which is useful as an agent for treating hyperlipidemia, hypercholesterolemia and atherosclerosis. A crystalline product was formed from amorphous I in a mixture of water and acetonitrile.


IT 147098-20-2

RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (crystalline bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt)

RN 147098-20-2 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



●1/2 Ca

OSC.G 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/576,774 (formula 8)

=> log y		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	332.24	531.37
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-47.85	-47.85

STN INTERNATIONAL LOGOFF AT 10:53:05 ON 16 JAN 2011